US20130004568A1 - Methods of treating hypertriglyceridemia - Google Patents

Methods of treating hypertriglyceridemia Download PDF

Info

Publication number
US20130004568A1
US20130004568A1 US13/610,247 US201213610247A US2013004568A1 US 20130004568 A1 US20130004568 A1 US 20130004568A1 US 201213610247 A US201213610247 A US 201213610247A US 2013004568 A1 US2013004568 A1 US 2013004568A1
Authority
US
United States
Prior art keywords
baseline
subject
pharmaceutical composition
compared
fasting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US13/610,247
Other versions
US8367652B2 (en
Inventor
Mehar Manku
Ian Osterloh
Pierre Wicker
Rene Braeckman
Paresh Soni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarin Pharmaceuticals Ireland Ltd
Original Assignee
Amarin Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20130004568(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US13/610,247 priority Critical patent/US8367652B2/en
Application filed by Amarin Pharmaceuticals Ireland Ltd filed Critical Amarin Pharmaceuticals Ireland Ltd
Assigned to AMARIN PHARMACEUTICALS IRELAND LIMITED reassignment AMARIN PHARMACEUTICALS IRELAND LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMARIN PHARMA INC.
Assigned to AMARIN PHARMA, INC. reassignment AMARIN PHARMA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OSTERLOH, IAN, MANKU, MEHAR, WICKER, PIERRE, SONI, PARESH, BRAECKMAN, RENE
Assigned to BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP reassignment BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP SECURITY AGREEMENT Assignors: AMARIN PHARMACEUTICALS IRELAND LIMITED
Publication of US20130004568A1 publication Critical patent/US20130004568A1/en
Publication of US8367652B2 publication Critical patent/US8367652B2/en
Application granted granted Critical
Assigned to CPPIB CREDIT EUROPE S.À R.L. reassignment CPPIB CREDIT EUROPE S.À R.L. PATENT SECURITY ASSIGNMENT AND ASSUMPTION AGREEMENT Assignors: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP
Assigned to CPPIB CREDIT EUROPE S.À R.L. reassignment CPPIB CREDIT EUROPE S.À R.L. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMARIN PHARMACEUTICALS IRELAND LIMITED
Assigned to AMARIN PHARMACEUTICALS IRELAND LIMITED reassignment AMARIN PHARMACEUTICALS IRELAND LIMITED RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CPPIB CREDIT EUROPE S.À R.L.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16ZINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00Subject matter not provided for in other main groups of this subclass

Definitions

  • Cardiovascular disease is one of the leading causes of death in the United States and most European countries. It is estimated that over 70 million people in the United States alone suffer from a cardiovascular disease or disorder including but not limited to high blood pressure, coronary heart disease, dislipidemia, congestive heart failure and stroke. A need exists for improved treatments for cardiovascular diseases and disorders.
  • the present invention provides methods of treating and/or preventing cardiovascular-related diseases and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
  • the composition contains not more than 10%, by weight, docosahexaenoic acid or derivative thereof, substantially no docosahexaenoic acid or derivative thereof, or no docosahexaenoic acid or derivative thereof.
  • eicosapentaenoic acid ethyl ester comprises at least 96%, by weight, of all fatty acids present in the composition; the composition contains not more than 4%, by weight, of total fatty acids other than eicosapentaenoic acid ethyl ester; and/or the composition contains about 0.1% to about 0.6% of at least one fatty acid other than eicosapentaenoic acid ethyl ester and docosahexaenoic acid (or derivative thereof).
  • a pharmaceutical composition useful in accordance with the invention comprises, consists of or consists essentially of at least 95% by weight ethyl eicosapentaenoate (EPA-E), about 0.2% to about 0.5% by weight ethyl octadecatetraenoate (ODTA-E), about 0.05% to about 0.25% by weight ethyl nonaecapentaenoate (NDPA-E), about 0.2% to about 0.45% by weight ethyl arachidonate (AA-E), about 0.3% to about 0.5% by weight ethyl eicosatetraenoate (ETA-E), and about 0.05% to about 0.32% ethyl heneicosapentaenoate (HPA-E).
  • the composition is present in a capsule shell.
  • the composition contains substantially no or no amount of docosahexaenoic acid (DHA) or derivative thereof such as ethyl-DHA (DHA)
  • the invention provides a method of treating moderate to severe hypertriglyceridemia comprising administering a composition as described herein to a subject in need thereof one to about four times per day.
  • the invention provides a method for treatment and/or prevention of a cardiovascular-related disease.
  • cardiovascular-related disease herein refers to any disease or disorder of the heart or blood vessels (i.e. arteries and veins) or any symptom thereof.
  • Non-limiting examples of cardiovascular-related disease and disorders include hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease, vascular disease, stroke, atherosclerosis, arrhythmia, hypertension, myocardial infarction, and other cardiovascular events.
  • treatment in relation a given disease or disorder, includes, but is not limited to, inhibiting the disease or disorder, for example, arresting the development of the disease or disorder; relieving the disease or disorder, for example, causing regression of the disease or disorder; or relieving a condition caused by or resulting from the disease or disorder, for example, relieving, preventing or treating symptoms of the disease or disorder.
  • prevention in relation to a given disease or disorder means: preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
  • the present invention provides a method of blood lipid therapy comprising administering to a subject or subject group in need thereof a pharmaceutical composition as described herein.
  • the subject or subject group has hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia and/or very high triglycerides.
  • the subject or subject group being treated has a baseline triglyceride level (or median baseline triglyceride level in the case of a subject group), fed or fasting, of at least about 300 mg/dl, at least about 400 mg/dl, at least about 500 mg/dl, at least about 600 mg/dl, at least about 700 mg/dl, at least about 800 mg/dl, at least about 900 mg/dl, at least about 1000 mg/dl, at least about 1100 mg/dl, at least about 1200 mg/dl, at least about 1300 mg/dl, at least about 1400 mg/dl, or at least about 1500 mg/dl, for example about 400 mg/dl to about 2500 mg/dl, about 450 mg/dl to about 2000 mg/dl or about 500 mg/dl to about 1500 mg/dl.
  • a baseline triglyceride level or median baseline triglyceride level in the case of a subject group
  • the subject or subject group being treated in accordance with methods of the invention has previously been treated with Lovaza® and has experienced an increase in, or no decrease in, LDL-C levels and/or non-HDL-C levels.
  • Lovaza® therapy is discontinued and replaced by a method of the present invention.
  • the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline absolute plasma level of free EPA (or mean thereof in the case of a subject group) not greater than about 0.70 nmol/ml, not greater than about 0.65 nmol/ml, not greater than about 0.60 nmol/ml, not greater than about 0.55 nmol/ml, not greater than about 0.50 nmol/ml, not greater than about 0.45 nmol/ml, or not greater than about 0.40 nmol/ml.
  • the subject or subject group being treated in accordance with methods of the invention exhibits a baseline fasting plasma level (or mean thereof) of free EPA, expressed as a percentage of total free fatty acid, of not more than about 3%, not more than about 2.5%, not more than about 2%, not more than about 1.5%, not more than about 1%, not more than about 0.75%, not more than about 0.5%, not more than about 0.25%, not more than about 0.2% or not more than about 0.15%.
  • free plasma EPA and/or total fatty acid levels are determined prior to initiating therapy.
  • the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline absolute plasma level of total fatty acid (or mean thereof) not greater than about 250 nmol/ml, not greater than about 200 nmol/ml, not greater than about 150 nmol/ml, not greater than about 100 nmol/ml, or not greater than about 50 nmol/ml.
  • the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline plasma, serum or red blood cell membrane EPA level not greater than about 70 ⁇ g/ml, not greater than about 60 ⁇ g/ml, not greater than about 50 ⁇ g/ml, not greater than about 40 ⁇ g/ml, not greater than about 30 ⁇ g/ml, or not greater than about 25 ⁇ g/ml.
  • methods of the present invention comprise a step of measuring the subject's (or subject group's mean) baseline lipid profile prior to initiating therapy.
  • methods of the invention comprise the step of identifying a subject or subject group having one or more of the following: baseline non-HDL-C value of about 200 mg/dl to about 400 mg/dl, for example at least about 210 mg/dl, at least about 220 mg/dl, at least about 230 mg/dl, at least about 240 mg/dl, at least about 250 mg/dl, at least about 260 mg/dl, at least about 270 mg/dl, at least about 280 mg/dl, at least about 290 mg/dl, or at least about 300 mg/dl; baseline total cholesterol value of about 250 mg/dl to about 400 mg/dl, for example at least about 260 mg/dl, at least about 270 mg/dl, at least about 280 mg/dl or at least about 290 mg/dl; baseline vLDL
  • the subject or subject group upon treatment in accordance with the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about Ito about 20 weeks, about Ito about 15 weeks, about 1 to about 12 weeks, about Ito about 10 weeks, about Ito about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits one or more of the following outcomes:
  • y a reduction or increase in one or more of serum phospholipid and/or red blood cell content of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), arachidonic acid (AA), palmitic acid (PA), staeridonic acid (SA) or oleic acid (OA) compared to baseline.
  • DHA docosahexaenoic acid
  • DPA docosapentaenoic acid
  • AA arachidonic acid
  • PA palmitic acid
  • SA staeridonic acid
  • OA oleic acid
  • the subject upon administering a composition of the invention to a subject, the subject exhibits a decrease in triglyceride levels, an increase in the concentrations of EPA and DPA (n-3) in red blood cells, and an increase of the ratio of EPA:arachidonic acid in red blood cells.
  • the subject upon administering a composition of the invention to a subject, the subject exhibits a decrease in triglyceride levels, an increase in the concentrations of EPA and DPA (n-3) in red blood cells, and an increase of the ratio of EPA:arachidonic acid in red blood cells.
  • the subject upon administering a composition of the invention to a subject exhibits a decrease in triglyceride levels, an increase in the concentrations of EPA and DPA (n-3) in red blood cells, and an increase of the ratio of EPA:arachidonic acid in red blood cells.
  • the subject upon administering a composition of the invention to a subject, exhibits a decrease in triglyceride levels, an increase
  • methods of the present invention comprise measuring baseline levels of one or more markers set forth in (a)-(y) above prior to dosing the subject or subject group.
  • the methods comprise administering a composition as disclosed herein to the subject after baseline levels of one or more markers set forth in (a)-(y) are determined, and subsequently taking an additional measurement of said one or more markers.
  • the subject or subject group upon treatment with a composition of the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about 1 to about 20 weeks, about 1 to about 15 weeks, about 1 to about 12 weeks, about 1 to about 10 weeks, about 1 to about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits any 2 or more of, any 3 or more of, any 4 or more of, any 5 or more of, any 6 or more of, any 7 or more of, any 8 or more of, any 9 or more of, any 10 or more of, any 11 or more of, any 12 or more of, any 13 or more of, any 14 or more of, any 15 or more of, any 16 or more of, any 17 or more of, any 18 or more of, any 19 or more of, any 20 or more of, any 21 or more of, any 22 or more of, any 23 or more, any 24 or more, or all 25 of outcomes (a
  • the subject or subject group upon treatment with a composition of the present invention, exhibits one or more of the following outcomes:
  • a reduction in triglyceride level of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline;
  • a reduction in lipoprotein (i) a reduction in lipoprotein (a) levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (n) substantially no change, no significant change, or a reduction (e.g. in the case of a diabetic subject) in fasting plasma glucose (FPG) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • FPG fasting plasma glucose
  • hemoglobin A 1c substantially no change, no significant change or a reduction in hemoglobin A 1c (HbA 1c ) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% (actual % change or median % change) compared to baseline;
  • a reduction in homeostasis model index insulin resistance of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • hsCRP high sensitivity C-reactive protein
  • (x) a reduction or increase in one or more of serum phospholipid and/or red blood cell DHA, DPA, AA, PA and/or OA of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) compared to baseline; and/or
  • methods of the present invention comprise measuring baseline levels of one or more markers set forth in (a)-(y) prior to dosing the subject or subject group. In another embodiment, the methods comprise administering a composition as disclosed herein to the subject after baseline levels of one or more markers set forth in (a)-(y) are determined, and subsequently taking a second measurement of the one or more markers as measured at baseline for comparison thereto.
  • the subject or subject group upon treatment with a composition of the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about 1 to about 20 weeks, about 1 to about 15 weeks, about 1 to about 12 weeks, about 1 to about 10 weeks, about 1 to about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits any 2 or more of, any 3 or more of, any 4 or more of, any 5 or more of, any 6 or more of, any 7 or more of, any 8 or more of, any 9 or more of, any 10 or more of, any 11 or more of, any 12 or more of, any 13 or more of, any 14 or more of, any 15 or more of, any 16 or more of, any 17 or more of, any 18 or more of, any 19 or more of, any 20 or more of, any 21 or more of, any 22 or more of, any 23 or more of, any 24 or more of, or all 26 or more
  • Parameters (a)-(y) can be measured in accordance with any clinically acceptable methodology.
  • triglycerides, total cholesterol, HDL-C and fasting blood sugar can be sample from serum and analyzed using standard photometry techniques.
  • VLDL-TG, LDL-C and VLDL-C can be calculated or determined using serum lipoprotein fractionation by preparative ultracentrifugation and subsequent quantitative analysis by refractometry or by analytic ultracentrifugal methodology.
  • Apo A1, Apo B and hsCRP can be determined from serum using standard nephelometry techniques.
  • Lipoprotein (a) can be determined from serum using standard turbidimetric immunoassay techniques.
  • LDL particle number and particle size can be determined using nuclear magnetic resonance (NMR) spectrometry.
  • Remnants lipoproteins and LDL-phospholipase A2 can be determined from EDTA plasma or serum and serum, respectively, using enzymatic immunoseparation techniques.
  • Oxidized LDL, intercellular adhesion molecule-1 and interleukin-6 levels can be determined from serum using standard enzyme immunoassay techniques. These techniques are described in detail in standard textbooks, for example Tietz Fundamentals of Clinical Chemistry, 6 th Ed. (Burtis, Ashwood and Borter Eds.), WB Saunders Company.
  • subjects fast for up to 12 hours prior to blood sample collection, for example about 10 hours.
  • the present invention provides a method of treating or preventing primary hypercholesterolemia and/or mixed dyslipidemia (Fredrickson Types IIa and IIb) in a patient in need thereof, comprising administering to the patient one or more compositions as disclosed herein.
  • the present invention provides a method of reducing triglyceride levels in a subject or subjects when treatment with a statin or niacin extended-release monotherapy is considered inadequate (Frederickson type IV hyperlipidemia).
  • the present invention provides a method of treating or preventing risk of recurrent nonfatal myocardial infarction in a patient with a history of myocardial infarction, comprising administering to the patient one or more compositions as disclosed herein.
  • the present invention provides a method of slowing progression of or promoting regression of atherosclerotic disease in a patient in need thereof, comprising administering to a subject in need thereof one or more compositions as disclosed herein.
  • the present invention provides a method of treating or preventing very high serum triglyceride levels (e.g. Types IV and V hyperlipidemia) in a patient in need thereof, comprising administering to the patient one or more compositions as disclosed herein.
  • very high serum triglyceride levels e.g. Types IV and V hyperlipidemia
  • the present invention provides a method of treating subjects having very high serum triglyceride levels (e.g. greater than 1000 mg/dl or greater than 2000 mg/dl) and that are at risk of developing pancreatitis, comprising administering to the patient one or more compositions as disclosed herein.
  • very high serum triglyceride levels e.g. greater than 1000 mg/dl or greater than 2000 mg/dl
  • a composition of the invention is administered to a subject in an amount sufficient to provide a daily dose of eicosapentaenoic acid of about 1 mg to about 10,000 mg, 25 about 5000 mg, about 50 to about 3000 mg, about 75 mg to about 2500 mg, or about 100 mg to about 1000 mg, for example about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg,
  • any of the methods disclosed herein are used in treatment or prevention of a subject or subjects that consume a traditional Western diet.
  • the methods of the invention include a step of identifying a subject as a Western diet consumer or prudent diet consumer and then treating the subject if the subject is deemed a Western diet consumer.
  • the term “Western diet” herein refers generally to a typical diet consisting of, by percentage of total calories, about 45% to about 50% carbohydrate, about 35% to about 40% fat, and about 10% to about 15% protein.
  • a Western diet may alternately or additionally be characterized by relatively high intakes of red and processed meats, sweets, refined grains, and desserts, for example more than 50%, more than 60% or more or 70% of total calories come from these sources.
  • a composition for use in methods of the invention comprises eicosapentaenoic acid, or a pharmaceutically acceptable ester, derivative, conjugate or salt thereof, or mixtures of any of the foregoing, collectively referred to herein as “EPA.”
  • EPA eicosapentaenoic acid
  • pharmaceutically acceptable in the present context means that the substance in question does not produce unacceptable toxicity to the subject or interaction with other components of the composition.
  • the EPA comprises all-cis eicosa-5,8,11,14,17-pentaenoic acid. In another embodiment, the EPA comprises an eicosapentaenoic acid ester. In another embodiment, the EPA comprises a C 1 -C 5 alkyl ester of eicosapentaenoic acid. In another embodiment, the EPA comprises eicosapentaenoic acid ethyl ester, eicosapentaenoic acid methyl ester, eicosapentaenoic acid propyl ester, or eicosapentaenoic acid butyl ester. In another embodiment, the EPA comprises
  • the EPA comprises all-cis eicosa-5,8,11,14,17-pentaenoic acid ethyl ester.
  • the EPA is in the form of ethyl-EPA, lithium EPA, mono-, di- or triglyceride EPA or any other ester or salt of EPA, or the free acid form of EPA.
  • the EPA may also be in the form of a 2-substituted derivative or other derivative which slows down its rate of oxidation but does not otherwise change its biological action to any substantial degree.
  • EPA is present in a composition useful in accordance with methods of the invention in an amount of about 50 mg to about 5000 mg, about 75 mg to about 2500 mg, or about 100 mg to about 1000 mg, for example about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1100 mg, about 1025 mg
  • a composition useful in accordance with the invention contains not more than about 10%, not more than about 9%, not more than about 8%, not more than about 7%, not more than about 6%, not more than about 5%, not more than about 4%, not more than about 3%, not more than about 2%, not more than about 1%, or not more than about 0.5%, by weight, docosahexaenoic acid (DHA), if any.
  • DHA docosahexaenoic acid
  • a composition of the invention contains substantially no docosahexaenoic acid.
  • a composition useful in the present invention contains no docosahexaenoic acid and/or derivative thereof.
  • EPA comprises at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, by weight, of all fatty acids present in a composition that is useful in methods of the present invention.
  • a composition of the invention comprises ultra-pure EPA.
  • ultra-pure as used herein with respect to EPA refers to a composition comprising at least 95% by weight EPA (as the term “EPA” is defined and exemplified herein).
  • Ultra-pure EPA comprises at least 96% by weight EPA, at least 97% by weight EPA, or at least 98% by weight EPA, wherein the EPA is any form of EPA as set forth herein.
  • a composition useful in accordance with methods of the invention contains less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5% or less than 0.25%, by weight of the total composition or by weight of the total fatty acid content, of any fatty acid other than EPA.
  • fatty acid other than EPA examples include linolenic acid (LA), arachidonic acid (AA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), stearadonic acid (STA), eicosatrienoic acid (ETA) and/or docosapentaenoic acid (DPA).
  • a composition useful in accordance with methods of the invention contains about 0.1% to about 4%, about 0.5% to about 3%, or about 1% to about 2%, by weight, of total fatty acids other than EPA and/or DHA.
  • a composition useful in accordance with the invention has one or more of the following features: (a) eicosapentaenoic acid ethyl ester represents at least about 96%, at least about 97%, or at least about 98%, by weight, of all fatty acids present in the composition; (b) the composition contains not more than about 4%, not more than about 3%, or not more than about 2%, by weight, of total fatty acids other than eicosapentaenoic acid ethyl ester; (c) the composition contains not more than about 0.6%, not more than about 0.5%, or not more than about 0.4% of any individual fatty acid other than eicosapentaenoic acid ethyl ester; (d) the composition has a refractive index (20° C.) of about 1 to about 2, about 1.2 to about 1.8 or about 1.4 to about 1.5; (e) the composition has a specific gravity (20° C.) of about 0.8 to about 1.0, about 0.
  • a composition useful in accordance with the invention comprises, consists of or consists essentially of at least 95% by weight ethyl eicosapentaenoate (EPA-E), about 0.2% to about 0.5% by weight ethyl octadecatetraenoate (ODTA-E), about 0.05% to about 0.25% by weight ethyl nonaecapentaenoate (NDPA-E), about 0.2% to about 0.45% by weight ethyl arachidonate (AA-E), about 0.3% to about 0.5% by weight ethyl eicosatetraenoate (ETA-E), and about 0.05% to about 0.32% ethyl heneicosapentaenoate (HPA-E).
  • the composition is present in a capsule shell.
  • compositions useful in accordance with the invention comprise, consist essential of, or consist of at least 95%, 96% or 97%, by weight, ethyl eicosapentaenoate, about 0.2% to about 0.5% by weight ethyl octadecatetraenoate, about 0.05% to about 0.25% by weight ethyl nonaecapentaenoate, about 0.2% to about 0.45% by weight ethyl arachidonate, about 0.3% to about 0.5% by weight ethyl eicosatetraenoate, and about 0.05% to about 0.32% ethyl heneicosapentaenoate.
  • the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, DHA or derivative there of such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative there of such as ethyl-DHA.
  • the composition further optionally comprises one or more antioxidants (e.g. tocopherol) or other impurities in an amount of not more than about 0.5% or not more than 0.05%.
  • the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol.
  • about 500 mg to about 1 g of the composition is provided in a capsule shell.
  • compositions useful in accordance with the invention comprise, consist essential of, or consist of at least 96% by weight ethyl eicosapentaenoate, about 0.22% to about 0.4% by weight ethyl octadecatetraenoate, about 0.075% to about 0.20% by weight ethyl nonaecapentaenoate, about 0.25% to about 0.40% by weight ethyl arachidonate, about 0.3% to about 0.4% by weight ethyl eicosatetraenoate and about 0.075% to about 0.25% ethyl heneicosapentaenoate.
  • the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, DHA or derivative there of such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative there of such as ethyl-DHA.
  • the composition further optionally comprises one or more antioxidants (e.g. tocopherol) or other impurities in an amount of not more than about 0.5% or not more than 0.05%.
  • the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol.
  • the invention provides a dosage form comprising about 500 mg to about 1 g of the foregoing composition in a capsule shell. In one embodiment, the dosage form is a gel or liquid capsule and is packaged in blister packages of about 1 to about 20 capsules per sheet.
  • compositions useful in accordance with the invention comprise, consist essential of, or consist of at least 96%, 97% or 98%, by weight, ethyl eicosapentaenoate, about 0.25% to about 0.38% by weight ethyl octadecatetraenoate, about 0.10% to about 0.15% by weight ethyl nonaecapentaenoate, about 0.25% to about 0.35% by weight ethyl arachidonate, about 0.31% to about 0.38% by weight ethyl eicosatetraenoate, and about 0.08% to about 0.20% ethyl heneicosapentaenoate.
  • the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, DHA or derivative there of such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative there of such as ethyl-DHA.
  • the composition further optionally comprises one or more antioxidants (e.g. tocopherol) or other impurities in an amount of not more than about 0.5% or not more than 0.05%.
  • the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol.
  • the invention provides a dosage form comprising about 500 mg to about 1 g of the foregoing composition in a capsule shell.
  • a composition as described herein is administered to a subject once or twice per day.
  • 1, 2, 3 or 4 capsules, each containing about 1 g of a composition as described herein are administered to a subject daily.
  • 1 or 2 capsules, each containing about 1 g of a composition as described herein are administered to the subject in the morning, for example between about 5 am and about 11 am, and 1 or 2 capsules, each containing about 1 g of a composition as described herein, are administered to the subject in the evening, for example between about 5 pm and about 11 pm.
  • a subject being treated in accordance with methods of the invention is not otherwise on lipid-altering therapy, for example statin, fibrate, niacin and/or ezetimibe therapy.
  • compositions useful in accordance with methods of the invention are orally deliverable.
  • oral administration include any form of delivery of a therapeutic agent or a composition thereof to a subject wherein the agent or composition is placed in the mouth of the subject, whether or not the agent or composition is swallowed.
  • oral administration includes buccal and sublingual as well as esophageal administration.
  • the composition is present in a capsule, for example a soft gelatin capsule.
  • a composition for use in accordance with the invention can be formulated as one or more dosage units.
  • dose unit and “dosage unit” herein refer to a portion of a pharmaceutical composition that contains an amount of a therapeutic agent suitable for a single administration to provide a therapeutic effect.
  • dosage units may be administered one to a plurality (i.e. 1 to about 10, 1 to 8, 1 to 6, 1 to 4 or 1 to 2) of times per day, or as many times as needed to elicit a therapeutic response.
  • the invention provides use of any composition described herein for treating moderate to severe hypertriglyceridemia in a subject in need thereof, comprising: providing a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl and administering to the subject a pharmaceutical composition as described herein.
  • the composition comprises about 1 g to about 4 g of eicosapentaenoic acid ethyl ester, wherein the composition contains substantially no docosahexaenoic acid.
  • compositions of the invention upon storage in a closed container maintained at room temperature, refrigerated (e.g. about 5 to about 5-10° C.) temperature, or frozen for a period of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months, exhibit at least about 90%, at least about 95%, at least about 97.5%, or at least about 99% of the active ingredient(s) originally present therein.
  • the invention provides use of a composition as described herein in manufacture of a medicament for treatment of any of a cardiovascular-related disease.
  • the subject is diabetic.
  • a composition as set forth herein is packaged together with instructions for using the composition to treat a cardiovascular disorder.
  • a multi-center, placebo-controlled randomized, double-blind, 12-week study with an open-label extension is performed to evaluate the efficacy and safety of AMR101 in patients with fasting triglyceride levels ⁇ 500 mg/dL.
  • the primary objective of the study is to determine the efficacy of AMR101 2 g daily and 4 g daily, compared to placebo, in lowering fasting TG levels in patients with fasting TG levels ⁇ 500 mg/dL and ⁇ 1500 mg/dL ( ⁇ 5.65 mmol/L and ⁇ 16.94 mmol/L).
  • statin therapy with or without ezetimibe
  • dose(s) must be stable for ⁇ 4 weeks prior to randomization.
  • lipid-altering medications niacin >200 mg/day, fibrates, fish oil, other products containing omega-3 fatty acids, or other herbal products or dietary supplements with potential lipid-altering effects
  • statin therapy with or without ezetimibe
  • the study will be a 58- to 60-week, Phase 3, multi-center study consisting of 3 study periods: (1) A 6- to 8-week screening period that includes a diet and lifestyle stabilization and washout period and a TG qualifying period; (2) A 12-week, double-blind, randomized, placebo-controlled treatment period; and (3) A 40-week, open-label, extension period.
  • the screening period includes a 4- or 6-week diet and lifestyle stabilization period and washout period followed by a 2-week TG qualifying period. s) must be stable for weeks prior to randomization.
  • the screening visit (Visit 1) will occur for all patients at either 6 weeks (for patients not on lipid-altering therapy at screening or for patients who will not need to discontinue their current lipid-altering therapy) or 8 weeks (for patients who will require washout of their current lipid-altering therapy at screening) before randomization, as follows:
  • eligible patients will enter the 2-week TG qualifying period and will have their fasting TG level measured at Visit 2 (Week-2) and Visit 3 (Week-1). Eligible patients must have an average fasting TG level 500 mg/dL and 1500 mg/dL (5.65 mmol/L and 16.94 mmol/L) to enter the 12-week double-blind treatment period.
  • the TG level for qualification will be based on the average (arithmetic mean) of the Visit 2 (Week-2) and Visit 3 (Week-1) values.
  • Eligible patients will be randomly assigned at Visit 4 (Week 0) to receive orally AMR101 2 g daily, AMR101 4 g daily, or placebo for the 12-week double-blind treatment period.
  • AMR101 is provided in 1 g liquid-filled, oblong, gelatin capsules.
  • the matching placebo capsule is filled with light liquid paraffin and contains 0 g of AMR101.
  • patients will take 2 capsules (AMR101 or matching placebo) in the morning and 2 in the evening for a total of 4 capsules per day.
  • Patients in the AMR101 2 g/day treatment group will receive 1 AMR101 1 g capsule and 1 matching placebo capsule in the morning and in the evening.
  • Patients in the AMR101 4 g/day treatment group will receive 2 AMR101 1 g capsules in the morning and evening.
  • Patients in the placebo group will receive 2 matching placebo capsules in the morning and evening. During the extension period, patients will receive open-label AMR101 4 g daily. Patients will take 2 AMR101 1 g capsules in the morning and 2 in the evening.
  • the primary efficacy variable for the double-blind treatment period is percent change in TG from baseline to Week 12 endpoint.
  • the secondary efficacy variables for the double-blind treatment period include the following:
  • the efficacy variable for the open-label extension period is percent change in fasting TG from extension baseline to end of treatment.
  • Safety assessments will include adverse events, clinical laboratory measurements (chemistry, hematology, and urinalysis), 12-lead electrocardiograms (ECGs), vital signs, and physical examinations
  • Week 12 endpoint will be defined as the average of Visit 6 (Week 11) and Visit 7 (Week 12) measurements. Week 12 endpoint for all other efficacy parameters will be the Visit 7 (Week 12) measurement.
  • the primary efficacy analysis will be performed using a 2-way analysis of covariance (ANCOVA) model with treatment as a factor and baseline TG value as a covariate.
  • ANCOVA 2-way analysis of covariance
  • the least-squares mean, standard error, and 2-tailed 95% confidence interval for each treatment group and for each comparison will be estimated.
  • the same 2-way ANCOVA model will be used for the analysis of secondary efficacy variables.
  • the primary efficacy variable will be the percent change in fasting TG levels from baseline to Week 12.
  • a sample size of 69 completed patients per treatment group will provide 90% power to detect a difference of 30% between AMR101 and placebo in percent change from baseline in fasting TG levels, assuming a standard deviation of 45% in TG measurements and a significance level of p ⁇ 0.01.
  • a total of 240 randomized patients is planned (80 patients per treatment group).

Abstract

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Description

  • This application is a continuation of co-pending U.S. application Ser. No. 13/349,153 filed on Jan. 12, 2012, which is a continuation of U.S. application Ser. No. 12/702,889 filed on Feb. 9, 2010 which claims priority to U.S. provisional application Ser. No. 61/151,291 filed Feb. 10, 2009 and U.S. provisional application Ser. No. 61/173,755 filed Apr. 29, 2009, each of which are incorporated by reference herein in their entireties.
  • BACKGROUND
  • Cardiovascular disease is one of the leading causes of death in the United States and most European countries. It is estimated that over 70 million people in the United States alone suffer from a cardiovascular disease or disorder including but not limited to high blood pressure, coronary heart disease, dislipidemia, congestive heart failure and stroke. A need exists for improved treatments for cardiovascular diseases and disorders.
  • SUMMARY
  • In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related diseases and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. In one embodiment, the composition contains not more than 10%, by weight, docosahexaenoic acid or derivative thereof, substantially no docosahexaenoic acid or derivative thereof, or no docosahexaenoic acid or derivative thereof. In another embodiment, eicosapentaenoic acid ethyl ester comprises at least 96%, by weight, of all fatty acids present in the composition; the composition contains not more than 4%, by weight, of total fatty acids other than eicosapentaenoic acid ethyl ester; and/or the composition contains about 0.1% to about 0.6% of at least one fatty acid other than eicosapentaenoic acid ethyl ester and docosahexaenoic acid (or derivative thereof).
  • In one embodiment, a pharmaceutical composition useful in accordance with the invention comprises, consists of or consists essentially of at least 95% by weight ethyl eicosapentaenoate (EPA-E), about 0.2% to about 0.5% by weight ethyl octadecatetraenoate (ODTA-E), about 0.05% to about 0.25% by weight ethyl nonaecapentaenoate (NDPA-E), about 0.2% to about 0.45% by weight ethyl arachidonate (AA-E), about 0.3% to about 0.5% by weight ethyl eicosatetraenoate (ETA-E), and about 0.05% to about 0.32% ethyl heneicosapentaenoate (HPA-E). In another embodiment, the composition is present in a capsule shell. In another embodiment, the composition contains substantially no or no amount of docosahexaenoic acid (DHA) or derivative thereof such as ethyl-DHA (DHA-E).
  • In another embodiment, the invention provides a method of treating moderate to severe hypertriglyceridemia comprising administering a composition as described herein to a subject in need thereof one to about four times per day.
  • These and other embodiments of the present invention will be disclosed in further detail herein below.
  • DETAILED DESCRIPTION
  • While the present invention is capable of being embodied in various forms, the description below of several embodiments is made with the understanding that the present disclosure is to be considered as an exemplification of the invention, and is not intended to limit the invention to the specific embodiments illustrated. Headings are provided for convenience only and are not to be construed to limit the invention in any manner. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.
  • The use of numerical values in the various quantitative values specified in this application, unless expressly indicated otherwise, are stated as approximations as though the minimum and maximum values within the stated ranges were both preceded by the word “about.” Also, the disclosure of ranges is intended as a continuous range including every value between the minimum and maximum values recited as well as any ranges that can be formed by such values. Also disclosed herein are any and all ratios (and ranges of any such ratios) that can be formed by dividing a disclosed numeric value into any other disclosed numeric value. Accordingly, the skilled person will appreciate that many such ratios, ranges, and ranges of ratios can be unambiguously derived from the numerical values presented herein and in all instances such ratios, ranges, and ranges of ratios represent various embodiments of the present invention.
  • In one embodiment, the invention provides a method for treatment and/or prevention of a cardiovascular-related disease. The term “cardiovascular-related disease” herein refers to any disease or disorder of the heart or blood vessels (i.e. arteries and veins) or any symptom thereof. Non-limiting examples of cardiovascular-related disease and disorders include hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease, vascular disease, stroke, atherosclerosis, arrhythmia, hypertension, myocardial infarction, and other cardiovascular events.
  • The term “treatment” in relation a given disease or disorder, includes, but is not limited to, inhibiting the disease or disorder, for example, arresting the development of the disease or disorder; relieving the disease or disorder, for example, causing regression of the disease or disorder; or relieving a condition caused by or resulting from the disease or disorder, for example, relieving, preventing or treating symptoms of the disease or disorder. The term “prevention” in relation to a given disease or disorder means: preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
  • In one embodiment, the present invention provides a method of blood lipid therapy comprising administering to a subject or subject group in need thereof a pharmaceutical composition as described herein. In another embodiment, the subject or subject group has hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia and/or very high triglycerides.
  • In another embodiment, the subject or subject group being treated has a baseline triglyceride level (or median baseline triglyceride level in the case of a subject group), fed or fasting, of at least about 300 mg/dl, at least about 400 mg/dl, at least about 500 mg/dl, at least about 600 mg/dl, at least about 700 mg/dl, at least about 800 mg/dl, at least about 900 mg/dl, at least about 1000 mg/dl, at least about 1100 mg/dl, at least about 1200 mg/dl, at least about 1300 mg/dl, at least about 1400 mg/dl, or at least about 1500 mg/dl, for example about 400 mg/dl to about 2500 mg/dl, about 450 mg/dl to about 2000 mg/dl or about 500 mg/dl to about 1500 mg/dl.
  • In one embodiment, the subject or subject group being treated in accordance with methods of the invention has previously been treated with Lovaza® and has experienced an increase in, or no decrease in, LDL-C levels and/or non-HDL-C levels. In one such embodiment, Lovaza® therapy is discontinued and replaced by a method of the present invention.
  • In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline absolute plasma level of free EPA (or mean thereof in the case of a subject group) not greater than about 0.70 nmol/ml, not greater than about 0.65 nmol/ml, not greater than about 0.60 nmol/ml, not greater than about 0.55 nmol/ml, not greater than about 0.50 nmol/ml, not greater than about 0.45 nmol/ml, or not greater than about 0.40 nmol/ml. In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a baseline fasting plasma level (or mean thereof) of free EPA, expressed as a percentage of total free fatty acid, of not more than about 3%, not more than about 2.5%, not more than about 2%, not more than about 1.5%, not more than about 1%, not more than about 0.75%, not more than about 0.5%, not more than about 0.25%, not more than about 0.2% or not more than about 0.15%. In one such embodiment, free plasma EPA and/or total fatty acid levels are determined prior to initiating therapy.
  • In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline absolute plasma level of total fatty acid (or mean thereof) not greater than about 250 nmol/ml, not greater than about 200 nmol/ml, not greater than about 150 nmol/ml, not greater than about 100 nmol/ml, or not greater than about 50 nmol/ml.
  • In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline plasma, serum or red blood cell membrane EPA level not greater than about 70 μg/ml, not greater than about 60 μg/ml, not greater than about 50 μg/ml, not greater than about 40 μg/ml, not greater than about 30 μg/ml, or not greater than about 25 μg/ml.
  • In another embodiment, methods of the present invention comprise a step of measuring the subject's (or subject group's mean) baseline lipid profile prior to initiating therapy. In another embodiment, methods of the invention comprise the step of identifying a subject or subject group having one or more of the following: baseline non-HDL-C value of about 200 mg/dl to about 400 mg/dl, for example at least about 210 mg/dl, at least about 220 mg/dl, at least about 230 mg/dl, at least about 240 mg/dl, at least about 250 mg/dl, at least about 260 mg/dl, at least about 270 mg/dl, at least about 280 mg/dl, at least about 290 mg/dl, or at least about 300 mg/dl; baseline total cholesterol value of about 250 mg/dl to about 400 mg/dl, for example at least about 260 mg/dl, at least about 270 mg/dl, at least about 280 mg/dl or at least about 290 mg/dl; baseline vLDL-C value of about 140 mg/dl to about 200 mg/dl, for example at least about 150 mg/dl, at least about 160 mg/dl, at least about 170 mg/dl, at least about 180 mg/dl or at least about 190 mg/dl; baseline HDL-C value of about 10 to about 60 mg/dl, for example not more than about 40 mg/dl, not more than about 35 mg/dl, not more than about 30 mg/dl, not more than about 25 mg/dl, not more than about 20 mg/dl, or not more than about 15 mg/dl; and/or baseline LDL-C value of about 50 to about 300 mg/dl, for example not less than about 100 mg/dl, not less than about 90 mg/dl, not less than about 80 mg/dl, not less than about 70 mg/dl, not less than about 60 mg/dl or not less than about 50 mg/dl.
  • In a related embodiment, upon treatment in accordance with the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about Ito about 20 weeks, about Ito about 15 weeks, about 1 to about 12 weeks, about Ito about 10 weeks, about Ito about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits one or more of the following outcomes:
  • (a) reduced triglyceride levels compared to baseline;
  • (b) reduced Apo B levels compared to baseline;
  • (c) increased HDL-C levels compared to baseline;
  • (d) no increase in LDL-C levels compared to baseline;
  • (e) a reduction in LDL-C levels compared to baseline;
  • (f) a reduction in non-HDL-C levels compared to baseline;
  • (g) a reduction in vLDL levels compared to baseline;
  • (h) an increase in apo A-I levels compared to baseline;
  • (i) an increase in apo A-I/apo B ratio compared to baseline;
  • (j) a reduction in lipoprotein A levels compared to baseline;
  • (k) a reduction in LDL particle number compared to baseline;
  • (l) an increase in LDL size compared to baseline;
  • (m) a reduction in remnant-like particle cholesterol compared to baseline;
  • (n) a reduction in oxidized LDL compared to baseline;
  • (o) no change or a reduction in fasting plasma glucose (FPG) compared to baseline;
  • (p) a reduction in hemoglobin A1c (HbA1c) compared to baseline;
  • (q) a reduction in homeostasis model insulin resistance compared to baseline;
  • (r) a reduction in lipoprotein associated phospholipase A2 compared to baseline;
  • (s) a reduction in intracellular adhesion molecule-1 compared to baseline;
  • (t) a reduction in interleukin-6 compared to baseline;
  • (u) a reduction in plasminogen activator inhibitor-1 compared to baseline;
  • (v) a reduction in high sensitivity C-reactive protein (hsCRP) compared to baseline;
  • (w) an increase in serum or plasma EPA compared to baseline;
  • (x) an increase in red blood cell (RBC) membrane EPA compared to baseline; and/or
  • (y) a reduction or increase in one or more of serum phospholipid and/or red blood cell content of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), arachidonic acid (AA), palmitic acid (PA), staeridonic acid (SA) or oleic acid (OA) compared to baseline.
  • In one embodiment, upon administering a composition of the invention to a subject, the subject exhibits a decrease in triglyceride levels, an increase in the concentrations of EPA and DPA (n-3) in red blood cells, and an increase of the ratio of EPA:arachidonic acid in red blood cells. In a related embodiment the subject exhibits substantially no or no increase in RBC DHA.
  • In one embodiment, methods of the present invention comprise measuring baseline levels of one or more markers set forth in (a)-(y) above prior to dosing the subject or subject group. In another embodiment, the methods comprise administering a composition as disclosed herein to the subject after baseline levels of one or more markers set forth in (a)-(y) are determined, and subsequently taking an additional measurement of said one or more markers.
  • In another embodiment, upon treatment with a composition of the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about 1 to about 20 weeks, about 1 to about 15 weeks, about 1 to about 12 weeks, about 1 to about 10 weeks, about 1 to about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits any 2 or more of, any 3 or more of, any 4 or more of, any 5 or more of, any 6 or more of, any 7 or more of, any 8 or more of, any 9 or more of, any 10 or more of, any 11 or more of, any 12 or more of, any 13 or more of, any 14 or more of, any 15 or more of, any 16 or more of, any 17 or more of, any 18 or more of, any 19 or more of, any 20 or more of, any 21 or more of, any 22 or more of, any 23 or more, any 24 or more, or all 25 of outcomes (a)-(y) described immediately above.
  • In another embodiment, upon treatment with a composition of the present invention, the subject or subject group exhibits one or more of the following outcomes:
  • (a) a reduction in triglyceride level of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline;
  • (b) a less than 30% increase, less than 20% increase, less than 10% increase, less than 5% increase or no increase in non-HDL-C levels or a reduction in non-HDL-C levels of at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline;
  • (c) substantially no change in HDL-C levels, no change in HDL-C levels, or an increase in HDL-C levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline;
  • (d) a less than 60% increase, a less than 50% increase, a less than 40% increase, a less than 30% increase, less than 20% increase, less than 10% increase, less than 5% increase or no increase in LDL-C levels or a reduction in LDL-C levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline;
  • (e) a decrease in Apo B levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline;
  • (f) a reduction in vLDL levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (g) an increase in apo A-I levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (h) an increase in apo A-I/apo B ratio of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (i) a reduction in lipoprotein (a) levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (j) a reduction in mean LDL particle number of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (k) an increase in mean LDL particle size of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (l) a reduction in remnant-like particle cholesterol of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (m) a reduction in oxidized LDL of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (n) substantially no change, no significant change, or a reduction (e.g. in the case of a diabetic subject) in fasting plasma glucose (FPG) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (o) substantially no change, no significant change or a reduction in hemoglobin A1c (HbA1c) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% (actual % change or median % change) compared to baseline;
  • (p) a reduction in homeostasis model index insulin resistance of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (q) a reduction in lipoprotein associated phospholipase A2 of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (r) a reduction in intracellular adhesion molecule-1 of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (s) a reduction in interleukin-6 of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (t) a reduction in plasminogen activator inhibitor-1 of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (u) a reduction in high sensitivity C-reactive protein (hsCRP) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline;
  • (v) an increase in serum, plasma and/or RBC EPA of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 100%, at least about 200% or at least about 400% (actual % change or median % change) compared to baseline;
  • (w) an increase in serum phospholipid and/or red blood cell membrane EPA of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, r at least about 50%, at least about 100%, at least about 200%, or at least about 400% (actual % change or median % change) compared to baseline;
  • (x) a reduction or increase in one or more of serum phospholipid and/or red blood cell DHA, DPA, AA, PA and/or OA of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) compared to baseline; and/or
  • (y) a reduction in total cholesterol of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) compared to baseline.
  • In one embodiment, methods of the present invention comprise measuring baseline levels of one or more markers set forth in (a)-(y) prior to dosing the subject or subject group. In another embodiment, the methods comprise administering a composition as disclosed herein to the subject after baseline levels of one or more markers set forth in (a)-(y) are determined, and subsequently taking a second measurement of the one or more markers as measured at baseline for comparison thereto.
  • In another embodiment, upon treatment with a composition of the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about 1 to about 20 weeks, about 1 to about 15 weeks, about 1 to about 12 weeks, about 1 to about 10 weeks, about 1 to about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits any 2 or more of, any 3 or more of, any 4 or more of, any 5 or more of, any 6 or more of, any 7 or more of, any 8 or more of, any 9 or more of, any 10 or more of, any 11 or more of, any 12 or more of, any 13 or more of, any 14 or more of, any 15 or more of, any 16 or more of, any 17 or more of, any 18 or more of, any 19 or more of, any 20 or more of, any 21 or more of, any 22 or more of, any 23 or more of, any 24 or more of, or all 26 or more of outcomes (a)-(y) described immediately above.
  • Parameters (a)-(y) can be measured in accordance with any clinically acceptable methodology. For example, triglycerides, total cholesterol, HDL-C and fasting blood sugar can be sample from serum and analyzed using standard photometry techniques. VLDL-TG, LDL-C and VLDL-C can be calculated or determined using serum lipoprotein fractionation by preparative ultracentrifugation and subsequent quantitative analysis by refractometry or by analytic ultracentrifugal methodology. Apo A1, Apo B and hsCRP can be determined from serum using standard nephelometry techniques. Lipoprotein (a) can be determined from serum using standard turbidimetric immunoassay techniques. LDL particle number and particle size can be determined using nuclear magnetic resonance (NMR) spectrometry. Remnants lipoproteins and LDL-phospholipase A2 can be determined from EDTA plasma or serum and serum, respectively, using enzymatic immunoseparation techniques. Oxidized LDL, intercellular adhesion molecule-1 and interleukin-6 levels can be determined from serum using standard enzyme immunoassay techniques. These techniques are described in detail in standard textbooks, for example Tietz Fundamentals of Clinical Chemistry, 6th Ed. (Burtis, Ashwood and Borter Eds.), WB Saunders Company.
  • In one embodiment, subjects fast for up to 12 hours prior to blood sample collection, for example about 10 hours.
  • In another embodiment, the present invention provides a method of treating or preventing primary hypercholesterolemia and/or mixed dyslipidemia (Fredrickson Types IIa and IIb) in a patient in need thereof, comprising administering to the patient one or more compositions as disclosed herein. In a related embodiment, the present invention provides a method of reducing triglyceride levels in a subject or subjects when treatment with a statin or niacin extended-release monotherapy is considered inadequate (Frederickson type IV hyperlipidemia).
  • In another embodiment, the present invention provides a method of treating or preventing risk of recurrent nonfatal myocardial infarction in a patient with a history of myocardial infarction, comprising administering to the patient one or more compositions as disclosed herein.
  • In another embodiment, the present invention provides a method of slowing progression of or promoting regression of atherosclerotic disease in a patient in need thereof, comprising administering to a subject in need thereof one or more compositions as disclosed herein.
  • In another embodiment, the present invention provides a method of treating or preventing very high serum triglyceride levels (e.g. Types IV and V hyperlipidemia) in a patient in need thereof, comprising administering to the patient one or more compositions as disclosed herein.
  • In another embodiment, the present invention provides a method of treating subjects having very high serum triglyceride levels (e.g. greater than 1000 mg/dl or greater than 2000 mg/dl) and that are at risk of developing pancreatitis, comprising administering to the patient one or more compositions as disclosed herein.
  • In one embodiment, a composition of the invention is administered to a subject in an amount sufficient to provide a daily dose of eicosapentaenoic acid of about 1 mg to about 10,000 mg, 25 about 5000 mg, about 50 to about 3000 mg, about 75 mg to about 2500 mg, or about 100 mg to about 1000 mg, for example about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1100 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1200 mg, about 1225 mg, about 1250 mg, about 1275 mg, about 1300 mg, about 1325 mg, about 1350 mg, about 1375 mg, about 1400 mg, about 1425 mg, about 1450 mg, about 1475 mg, about 1500 mg, about 1525 mg, about 1550 mg, about 1575 mg, about 1600 mg, about 1625 mg, about 1650 mg, about 1675 mg, about 1700 mg, about 1725 mg, about 1750 mg, about 1775 mg, about 1800 mg, about 1825 mg, about 1850 mg, about 1875 mg, about 1900 mg, about 1925 mg, about 1950 mg, about 1975 mg, about 2000 mg, about 2025 mg, about 2050 mg, about 2075 mg, about 2100 mg, about 2125 mg, about 2150 mg, about 2175 mg, about 2200 mg, about 2225 mg, about 2250 mg, about 2275 mg, about 2300 mg, about 2325 mg, about 2350 mg, about 2375 mg, about 2400 mg, about 2425 mg, about 2450 mg, about 2475 mg or about 2500 mg.
  • In another embodiment, any of the methods disclosed herein are used in treatment or prevention of a subject or subjects that consume a traditional Western diet. In one embodiment, the methods of the invention include a step of identifying a subject as a Western diet consumer or prudent diet consumer and then treating the subject if the subject is deemed a Western diet consumer. The term “Western diet” herein refers generally to a typical diet consisting of, by percentage of total calories, about 45% to about 50% carbohydrate, about 35% to about 40% fat, and about 10% to about 15% protein. A Western diet may alternately or additionally be characterized by relatively high intakes of red and processed meats, sweets, refined grains, and desserts, for example more than 50%, more than 60% or more or 70% of total calories come from these sources.
  • In one embodiment, a composition for use in methods of the invention comprises eicosapentaenoic acid, or a pharmaceutically acceptable ester, derivative, conjugate or salt thereof, or mixtures of any of the foregoing, collectively referred to herein as “EPA.” The term “pharmaceutically acceptable” in the present context means that the substance in question does not produce unacceptable toxicity to the subject or interaction with other components of the composition.
  • In one embodiment, the EPA comprises all-cis eicosa-5,8,11,14,17-pentaenoic acid. In another embodiment, the EPA comprises an eicosapentaenoic acid ester. In another embodiment, the EPA comprises a C1-C5 alkyl ester of eicosapentaenoic acid. In another embodiment, the EPA comprises eicosapentaenoic acid ethyl ester, eicosapentaenoic acid methyl ester, eicosapentaenoic acid propyl ester, or eicosapentaenoic acid butyl ester. In another embodiment, the EPA comprises
  • In one embodiment, the EPA comprises all-cis eicosa-5,8,11,14,17-pentaenoic acid ethyl ester.
  • In another embodiment, the EPA is in the form of ethyl-EPA, lithium EPA, mono-, di- or triglyceride EPA or any other ester or salt of EPA, or the free acid form of EPA. The EPA may also be in the form of a 2-substituted derivative or other derivative which slows down its rate of oxidation but does not otherwise change its biological action to any substantial degree.
  • In another embodiment, EPA is present in a composition useful in accordance with methods of the invention in an amount of about 50 mg to about 5000 mg, about 75 mg to about 2500 mg, or about 100 mg to about 1000 mg, for example about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1100 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1200 mg, about 1225 mg, about 1250 mg, about 1275 mg, about 1300 mg, about 1325 mg, about 1350 mg, about 1375 mg, about 1400 mg, about 1425 mg, about 1450 mg, about 1475 mg, about 1500 mg, about 1525 mg, about 1550 mg, about 1575 mg, about 1600 mg, about 1625 mg, about 1650 mg, about 1675 mg, about 1700 mg, about 1725 mg, about 1750 mg, about 1775 mg, about 1800 mg, about 1825 mg, about 1850 mg, about 1875 mg, about 1900 mg, about 1925 mg, about 1950 mg, about 1975 mg, about 2000 mg, about 2025 mg, about 2050 mg, about 2075 mg, about 2100 mg, about 2125 mg, about 2150 mg, about 2175 mg, about 2200 mg, about 2225 mg, about 2250 mg, about 2275 mg, about 2300 mg, about 2325 mg, about 2350 mg, about 2375 mg, about 2400 mg, about 2425 mg, about 2450 mg, about 2475 mg or about 2500 mg.
  • In another embodiment, a composition useful in accordance with the invention contains not more than about 10%, not more than about 9%, not more than about 8%, not more than about 7%, not more than about 6%, not more than about 5%, not more than about 4%, not more than about 3%, not more than about 2%, not more than about 1%, or not more than about 0.5%, by weight, docosahexaenoic acid (DHA), if any. In another embodiment, a composition of the invention contains substantially no docosahexaenoic acid. In still another embodiment, a composition useful in the present invention contains no docosahexaenoic acid and/or derivative thereof.
  • In another embodiment, EPA comprises at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, by weight, of all fatty acids present in a composition that is useful in methods of the present invention.
  • In one embodiment, a composition of the invention comprises ultra-pure EPA. The term “ultra-pure” as used herein with respect to EPA refers to a composition comprising at least 95% by weight EPA (as the term “EPA” is defined and exemplified herein). Ultra-pure EPA comprises at least 96% by weight EPA, at least 97% by weight EPA, or at least 98% by weight EPA, wherein the EPA is any form of EPA as set forth herein.
  • In another embodiment, a composition useful in accordance with methods of the invention contains less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5% or less than 0.25%, by weight of the total composition or by weight of the total fatty acid content, of any fatty acid other than EPA. Illustrative examples of a “fatty acid other than EPA” include linolenic acid (LA), arachidonic acid (AA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), stearadonic acid (STA), eicosatrienoic acid (ETA) and/or docosapentaenoic acid (DPA). In another embodiment, a composition useful in accordance with methods of the invention contains about 0.1% to about 4%, about 0.5% to about 3%, or about 1% to about 2%, by weight, of total fatty acids other than EPA and/or DHA.
  • In another embodiment, a composition useful in accordance with the invention has one or more of the following features: (a) eicosapentaenoic acid ethyl ester represents at least about 96%, at least about 97%, or at least about 98%, by weight, of all fatty acids present in the composition; (b) the composition contains not more than about 4%, not more than about 3%, or not more than about 2%, by weight, of total fatty acids other than eicosapentaenoic acid ethyl ester; (c) the composition contains not more than about 0.6%, not more than about 0.5%, or not more than about 0.4% of any individual fatty acid other than eicosapentaenoic acid ethyl ester; (d) the composition has a refractive index (20° C.) of about 1 to about 2, about 1.2 to about 1.8 or about 1.4 to about 1.5; (e) the composition has a specific gravity (20° C.) of about 0.8 to about 1.0, about 0.85 to about 0.95 or about 0.9 to about 0.92; (e) the composition contains not more than about 20 ppm, not more than about 15 ppm or not more than about 10 ppm heavy metals, (f) the composition contains not more than about 5 ppm, not more than about 4 ppm, not more than about 3 ppm, or not more than about 2 ppm arsenic, and/or (g) the composition has a peroxide value of not more than about 5 meq/kg, not more than about 4 meq/kg, not more than about 3 meq/kg, or not more than about 2 meq/kg.
  • In another embodiment, a composition useful in accordance with the invention comprises, consists of or consists essentially of at least 95% by weight ethyl eicosapentaenoate (EPA-E), about 0.2% to about 0.5% by weight ethyl octadecatetraenoate (ODTA-E), about 0.05% to about 0.25% by weight ethyl nonaecapentaenoate (NDPA-E), about 0.2% to about 0.45% by weight ethyl arachidonate (AA-E), about 0.3% to about 0.5% by weight ethyl eicosatetraenoate (ETA-E), and about 0.05% to about 0.32% ethyl heneicosapentaenoate (HPA-E). In another embodiment, the composition is present in a capsule shell.
  • In another embodiment, compositions useful in accordance with the invention comprise, consist essential of, or consist of at least 95%, 96% or 97%, by weight, ethyl eicosapentaenoate, about 0.2% to about 0.5% by weight ethyl octadecatetraenoate, about 0.05% to about 0.25% by weight ethyl nonaecapentaenoate, about 0.2% to about 0.45% by weight ethyl arachidonate, about 0.3% to about 0.5% by weight ethyl eicosatetraenoate, and about 0.05% to about 0.32% ethyl heneicosapentaenoate. Optionally, the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, DHA or derivative there of such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative there of such as ethyl-DHA. The composition further optionally comprises one or more antioxidants (e.g. tocopherol) or other impurities in an amount of not more than about 0.5% or not more than 0.05%. In another embodiment, the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol. In another embodiment, about 500 mg to about 1 g of the composition is provided in a capsule shell.
  • In another embodiment, compositions useful in accordance with the invention comprise, consist essential of, or consist of at least 96% by weight ethyl eicosapentaenoate, about 0.22% to about 0.4% by weight ethyl octadecatetraenoate, about 0.075% to about 0.20% by weight ethyl nonaecapentaenoate, about 0.25% to about 0.40% by weight ethyl arachidonate, about 0.3% to about 0.4% by weight ethyl eicosatetraenoate and about 0.075% to about 0.25% ethyl heneicosapentaenoate. Optionally, the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, DHA or derivative there of such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative there of such as ethyl-DHA. The composition further optionally comprises one or more antioxidants (e.g. tocopherol) or other impurities in an amount of not more than about 0.5% or not more than 0.05%. In another embodiment, the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol. In another embodiment, the invention provides a dosage form comprising about 500 mg to about 1 g of the foregoing composition in a capsule shell. In one embodiment, the dosage form is a gel or liquid capsule and is packaged in blister packages of about 1 to about 20 capsules per sheet.
  • In another embodiment, compositions useful in accordance with the invention comprise, consist essential of, or consist of at least 96%, 97% or 98%, by weight, ethyl eicosapentaenoate, about 0.25% to about 0.38% by weight ethyl octadecatetraenoate, about 0.10% to about 0.15% by weight ethyl nonaecapentaenoate, about 0.25% to about 0.35% by weight ethyl arachidonate, about 0.31% to about 0.38% by weight ethyl eicosatetraenoate, and about 0.08% to about 0.20% ethyl heneicosapentaenoate. Optionally, the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, DHA or derivative there of such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative there of such as ethyl-DHA. The composition further optionally comprises one or more antioxidants (e.g. tocopherol) or other impurities in an amount of not more than about 0.5% or not more than 0.05%. In another embodiment, the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol. In another embodiment, the invention provides a dosage form comprising about 500 mg to about 1 g of the foregoing composition in a capsule shell.
  • In another embodiment, a composition as described herein is administered to a subject once or twice per day. In another embodiment, 1, 2, 3 or 4 capsules, each containing about 1 g of a composition as described herein, are administered to a subject daily. In another embodiment, 1 or 2 capsules, each containing about 1 g of a composition as described herein, are administered to the subject in the morning, for example between about 5 am and about 11 am, and 1 or 2 capsules, each containing about 1 g of a composition as described herein, are administered to the subject in the evening, for example between about 5 pm and about 11 pm.
  • In one embodiment, a subject being treated in accordance with methods of the invention is not otherwise on lipid-altering therapy, for example statin, fibrate, niacin and/or ezetimibe therapy.
  • In another embodiment, compositions useful in accordance with methods of the invention are orally deliverable. The terms “orally deliverable” or “oral administration” herein include any form of delivery of a therapeutic agent or a composition thereof to a subject wherein the agent or composition is placed in the mouth of the subject, whether or not the agent or composition is swallowed. Thus “oral administration” includes buccal and sublingual as well as esophageal administration. In one embodiment, the composition is present in a capsule, for example a soft gelatin capsule.
  • A composition for use in accordance with the invention can be formulated as one or more dosage units. The terms “dose unit” and “dosage unit” herein refer to a portion of a pharmaceutical composition that contains an amount of a therapeutic agent suitable for a single administration to provide a therapeutic effect. Such dosage units may be administered one to a plurality (i.e. 1 to about 10, 1 to 8, 1 to 6, 1 to 4 or 1 to 2) of times per day, or as many times as needed to elicit a therapeutic response.
  • In another embodiment, the invention provides use of any composition described herein for treating moderate to severe hypertriglyceridemia in a subject in need thereof, comprising: providing a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl and administering to the subject a pharmaceutical composition as described herein. In one embodiment, the composition comprises about 1 g to about 4 g of eicosapentaenoic acid ethyl ester, wherein the composition contains substantially no docosahexaenoic acid.
  • In one embodiment, compositions of the invention, upon storage in a closed container maintained at room temperature, refrigerated (e.g. about 5 to about 5-10° C.) temperature, or frozen for a period of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months, exhibit at least about 90%, at least about 95%, at least about 97.5%, or at least about 99% of the active ingredient(s) originally present therein.
  • In one embodiment, the invention provides use of a composition as described herein in manufacture of a medicament for treatment of any of a cardiovascular-related disease. In another embodiment, the subject is diabetic.
  • In one embodiment, a composition as set forth herein is packaged together with instructions for using the composition to treat a cardiovascular disorder.
  • EXAMPLES
  • A multi-center, placebo-controlled randomized, double-blind, 12-week study with an open-label extension is performed to evaluate the efficacy and safety of AMR101 in patients with fasting triglyceride levels ≧500 mg/dL. The primary objective of the study is to determine the efficacy of AMR101 2 g daily and 4 g daily, compared to placebo, in lowering fasting TG levels in patients with fasting TG levels ≧500 mg/dL and ≧1500 mg/dL (≧5.65 mmol/L and ≧16.94 mmol/L).
  • The secondary objectives of this study are the following:
    • 1. To determine the safety and tolerability of AMR101 2 g daily and 4 g daily;
    • 2. To determine the effect of AMR101 on lipid and apolipoprotein profiles;
    • 3. To determine the effect of AMR101 on low-density lipoprotein (LDL) particle number and size;
    • 4. To determine the effect of AMR101 on oxidized LDL;
    • 5. To determine the effect of AMR101 on fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c);
    • 6. To determine the effect of AMR101 on insulin resistance;
    • 7. To determine the effect of AMR101 on high-sensitivity C-reactive protein (hsCRP);
    • 8. To determine the effects of AMR101 2 g daily and 4 g daily on the incorporation of fatty acids into red blood cell membranes and into plasma phospholipids;
    • 9. To explore the relationship between baseline fasting TG levels and the reduction in fasting TG levels; and
    • 10. To explore the relationship between an increase in red blood cell membrane eicosapentaenoic acid (EPA) concentrations and the reduction in fasting TG levels.
  • The population for this study is men and women (women of childbearing potential will need to be on contraception or practice abstinence) >18 years of age with a body mass index ≦45 kg/m2 who are not on lipid-altering therapy or are currently on lipid-altering therapy. Patients currently on statin therapy (with or without ezetimibe) will be evaluated by the investigator as to whether this therapy can be safely discontinued at screening, or if it should be continued. If statin therapy (with or without ezetimibe) is to be continued, dose(s) must be stable for ≧4 weeks prior to randomization. Patients taking non-statin, lipid-altering medications (niacin >200 mg/day, fibrates, fish oil, other products containing omega-3 fatty acids, or other herbal products or dietary supplements with potential lipid-altering effects), either alone or in combination with statin therapy (with or without ezetimibe), must be able to safely discontinue non-statin, lipid-altering therapy at screening.
  • Approximately 240 patients will be randomized at approximately 50 centers in North America, South America, Central America, Europe, India, and South Africa. The study will be a 58- to 60-week, Phase 3, multi-center study consisting of 3 study periods: (1) A 6- to 8-week screening period that includes a diet and lifestyle stabilization and washout period and a TG qualifying period; (2) A 12-week, double-blind, randomized, placebo-controlled treatment period; and (3) A 40-week, open-label, extension period.
  • During the screening period and double-blind treatment period, all visits are to be within ±3 days of the scheduled time. During the open-label extension period, all visits are to be within ±7 days of the scheduled time. The screening period includes a 4- or 6-week diet and lifestyle stabilization period and washout period followed by a 2-week TG qualifying period. s) must be stable for weeks prior to randomization.
  • The screening visit (Visit 1) will occur for all patients at either 6 weeks (for patients not on lipid-altering therapy at screening or for patients who will not need to discontinue their current lipid-altering therapy) or 8 weeks (for patients who will require washout of their current lipid-altering therapy at screening) before randomization, as follows:
  • Patients who do not require a washout: The screening visit will occur at Visit 1 (Week-6). Eligible patients will enter a 4-week diet and lifestyle stabilization period. At the screening visit, all patients will receive counseling regarding the importance of the National Cholesterol Education Program (NCEP) Therapeutic Lifestyle Changes (TLC) diet and will receive instructions on how to follow this diet. Patients who will require a washout: The screening visit will occur at Visit 1 (Week-8). Eligible patients will begin a 6-week washout period at the screening visit. Patients will receive counseling regarding the NCEP TLC diet and will receive instructions on how to follow this diet. Site personnel will contact patients who do not qualify for participation based on screening laboratory test results to instruct them to resume their prior lipid-altering medications.
  • At the end of the 4-week diet and lifestyle stabilization period or the 6-week diet and stabilization and washout period, eligible patients will enter the 2-week TG qualifying period and will have their fasting TG level measured at Visit 2 (Week-2) and Visit 3 (Week-1). Eligible patients must have an average fasting TG level 500 mg/dL and 1500 mg/dL (5.65 mmol/L and 16.94 mmol/L) to enter the 12-week double-blind treatment period. The TG level for qualification will be based on the average (arithmetic mean) of the Visit 2 (Week-2) and Visit 3 (Week-1) values. If a patient's average TG level from Visit 2 and Visit 3 falls outside the required range for entry into the study, an additional sample for fasting TG measurement can be collected 1 week later at Visit 3.1. If a third sample is collected at Visit 3.1, entry into the study will be based on the average (arithmetic mean) of the values from Visit 3 and Visit 3.1.
  • After confirmation of qualifying fasting TG values, eligible patients will enter a 12-week, randomized, double-blind treatment period. At Visit 4 (Week 0), patients will be randomly assigned to 1 of the following treatment groups:
    • AMR101 2 g daily,
    • AMR101 4 g daily, or
    • Placebo.
  • During the double-blind treatment period, patients will return to the site at Visit 5 (Week 4), Visit 6 (Week 11), and Visit 7 (Week 12) for efficacy and safety evaluations.
  • Patients who complete the 12-week double-blind treatment period will be eligible to enter a 40-week, open-label, extension period at Visit 7 (Week 12). All patients will receive open-label AMR101 4 g daily. From Visit 8 (Week 16) until the end of the study, changes to the lipid-altering regimen are permitted (e.g., initiating or raising the dose of statin or adding non-statin, lipid-altering medications to the regimen), as guided by standard practice and prescribing information. After Visit 8 (Week 16), patients will return to the site every 12 weeks until the last visit at Visit 11 (Week 52).
  • Eligible patients will be randomly assigned at Visit 4 (Week 0) to receive orally AMR101 2 g daily, AMR101 4 g daily, or placebo for the 12-week double-blind treatment period. AMR101 is provided in 1 g liquid-filled, oblong, gelatin capsules. The matching placebo capsule is filled with light liquid paraffin and contains 0 g of AMR101. During the double-blind treatment period, patients will take 2 capsules (AMR101 or matching placebo) in the morning and 2 in the evening for a total of 4 capsules per day. Patients in the AMR101 2 g/day treatment group will receive 1 AMR101 1 g capsule and 1 matching placebo capsule in the morning and in the evening. Patients in the AMR101 4 g/day treatment group will receive 2 AMR101 1 g capsules in the morning and evening.
  • Patients in the placebo group will receive 2 matching placebo capsules in the morning and evening. During the extension period, patients will receive open-label AMR101 4 g daily. Patients will take 2 AMR101 1 g capsules in the morning and 2 in the evening.
  • The primary efficacy variable for the double-blind treatment period is percent change in TG from baseline to Week 12 endpoint. The secondary efficacy variables for the double-blind treatment period include the following:
    • Percent changes in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), calculated low-density lipoprotein cholesterol (LDL-C), calculated non-high-density lipoprotein cholesterol (non-HDL-C), and very low-density lipoprotein cholesterol (VLDL-C) from baseline to Week 12 endpoint;
    • Percent change in very low-density lipoprotein TG from baseline to Week 12;
    • Percent changes in apolipoprotein A-I (apo A-I), apolipoprotein B (apo B), and apo A-I/apo B ratio from baseline to Week 12;
    • Percent changes in lipoprotein(a) from baseline to Week 12 (selected sites only);
    • Percent changes in LDL particle number and size, measured by nuclear magnetic resonance, from baseline to Week 12 (selected sites only);
    • Percent change in remnant-like particle cholesterol from baseline to Week 12 (selected sites only);
    • Percent change in oxidized LDL from baseline to Week 12 (selected sites only);
    • Changes in FPG and HbA1c from baseline to Week 12;
    • Change in insulin resistance, as assessed by the homeostasis model index insulin resistance, from baseline to Week 12;
    • Percent change in lipoprotein associated phospholipase A2 from baseline to Week 12 (selected sites only);
    • Change in intracellular adhesion molecule-1 from baseline to Week 12 (selected sites only);
    • Change in interleukin-6 from baseline to Week 12 (selected sites only);
    • Change in plasminogen activator inhibitor-1 from baseline to Week 12 (selected sites only);
    • Change in hsCRP from baseline to Week 12 (selected sites only);
    • Change in serum phospholipid EPA content from baseline to Week 12;
    • Change in red blood cell membrane EPA content from baseline to Week 12; and
    • Change in serum phospholipid and red blood cell membrane content in the following fatty acids from baseline to Week 12: docosapentaenoic acid, docosahexaenoic acid, arachidonic acid, palmitic acid, stearic acid, and oleic acid.
  • The efficacy variable for the open-label extension period is percent change in fasting TG from extension baseline to end of treatment. Safety assessments will include adverse events, clinical laboratory measurements (chemistry, hematology, and urinalysis), 12-lead electrocardiograms (ECGs), vital signs, and physical examinations
  • For TG, TC, HDL-C, calculated LDL-C, calculated non-HDL-C, and VLDL-C, baseline will be defined as the average of Visit 4 (Week 0) and the preceding lipid qualifying visit (either Visit 3 [Week-1] or if it occurs, Visit 3.1) measurements. Baseline for all other efficacy parameters will be the Visit 4 (Week 0) measurement.
  • For TC, HDL-C, calculated LDL-C, calculated non-HDL-C, and VLDL-C, Week 12 endpoint will be defined as the average of Visit 6 (Week 11) and Visit 7 (Week 12) measurements. Week 12 endpoint for all other efficacy parameters will be the Visit 7 (Week 12) measurement.
  • The primary efficacy analysis will be performed using a 2-way analysis of covariance (ANCOVA) model with treatment as a factor and baseline TG value as a covariate. The least-squares mean, standard error, and 2-tailed 95% confidence interval for each treatment group and for each comparison will be estimated. The same 2-way ANCOVA model will be used for the analysis of secondary efficacy variables.
  • The primary analysis will be repeated for the per-protocol population to confirm the robustness of the results for the intent-to-treat population.
  • The primary efficacy variable will be the percent change in fasting TG levels from baseline to Week 12. A sample size of 69 completed patients per treatment group will provide 90% power to detect a difference of 30% between AMR101 and placebo in percent change from baseline in fasting TG levels, assuming a standard deviation of 45% in TG measurements and a significance level of p <0.01. To accommodate a 15% drop-out rate from randomization to completion of the double-blind treatment period, a total of 240 randomized patients is planned (80 patients per treatment group).

Claims (18)

1. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl who does not receive concurrent lipid altering therapy comprising: administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 96%, by weight of all fatty acids present, ethyl eicosapentaenoate and substantially no docosahexaenoic acid or its esters for a period of about 12 weeks to effect a reduction in triglycerides without substantially increasing LDL-C compared to baseline.
2. The method of claim 1, wherein the pharmaceutical composition is administered to the subject 1 to 4 times per day.
3. The method of claim 2, wherein the pharmaceutical composition is present in one or more capsules.
4. The method of claim 1, wherein the subject has a fasting baseline LDL-C from about 40 mg/dl to about 115 mg/dl.
5. The method of claim 1, wherein subject has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl, a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl, a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl, and/or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.
6. The method of claim 1, comprising administering to the subject about 4 g of the pharmaceutical composition daily for the period of at least about 12 weeks to effect a reduction in fasting triglycerides of at least about 10% without substantially increasing LDL-C compared to baseline.
7. The method of claim 1, comprising administering to the subject about 4 g of the pharmaceutical composition daily for the period of at least about 12 weeks to effect a reduction in fasting triglycerides of at least about 25% without substantially increasing LDL-C compared to baseline.
8. The method of claim 1, comprising administering to the subject about 4 g of the pharmaceutical composition daily for the period of at least about 12 weeks to effect a reduction in apolipoprotein B compared to baseline.
9. The method of claim 1, comprising administering to the subject about 4 g of the pharmaceutical composition daily for the period of at least about 12 weeks to effect a reduction in VLDL-C compared to baseline.
10. A method of lowering triglycerides in a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl comprising: administering orally to the subject about 4 g per day of a pharmaceutical composition eicosapentaenoate and substantially no docosahexaenoic acid or its esters, which when orally administered in a first patient population having said baseline triglyceride level and receiving, for a period of twelve weeks, 4 g per day of the pharmaceutical composition without a concurrent lipid altering therapy, is effective to reduce said baseline triglyceride level without substantially increasing LDL-C compared to a second patient population having said baseline triglyceride level that has not received the pharmaceutical composition and a concurrent lipid altering therapy.
11. The method of claim 10, wherein the pharmaceutical composition is administered to the subject 1 to 4 times per day.
12. The method of claim 11, wherein the pharmaceutical composition is present in one or more capsules.
13. The method of claim 10, wherein the subject has a fasting baseline LDL-C from about 40 mg/dl to about 115 mg/dl.
14. The method of claim 10, wherein subject has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl, a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl, a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl, and/or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.
15. The method of claim 10, wherein the pharmaceutical composition, when orally administered daily to the first patient population for the period of twelve weeks is effective to reduce the baseline triglyceride level by at least about 10% without substantially increasing LDL-C compared to the second patient population that has not received the pharmaceutical composition and a concurrent lipid altering therapy.
16. The method of claim 10, wherein the pharmaceutical composition, when orally administered daily to the first patient population for the period of twelve weeks is effective to reduce the baseline triglyceride level by at least about 25% without substantially increasing LDL-C compared to the second patient population that has not received the pharmaceutical composition and a concurrent lipid altering therapy.
17. The method of claim 10, wherein the pharmaceutical composition, when orally administered daily to the first patient population for the period of twelve weeks is effective to reduce apolipoprotein B compared to the second patient population that has not received the pharmaceutical composition and a concurrent lipid altering therapy.
18. The method of claim 10, wherein the pharmaceutical composition, when orally administered daily to the first patient population for the period of twelve weeks is effective to reduce VLDL-C compared to the second patient population that has not received the pharmaceutical composition and a concurrent lipid altering therapy.
US13/610,247 2009-02-10 2012-09-11 Methods of treating hypertriglyceridemia Active US8367652B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/610,247 US8367652B2 (en) 2009-02-10 2012-09-11 Methods of treating hypertriglyceridemia

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15129109P 2009-02-10 2009-02-10
US17375509P 2009-04-29 2009-04-29
US12/702,889 US8293727B2 (en) 2009-02-10 2010-02-09 Methods of treating hypertriglyceridemia
US13/349,153 US8293728B2 (en) 2009-02-10 2012-01-12 Methods of treating hypertriglyceridemia
US13/610,247 US8367652B2 (en) 2009-02-10 2012-09-11 Methods of treating hypertriglyceridemia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/349,153 Continuation US8293728B2 (en) 2009-02-10 2012-01-12 Methods of treating hypertriglyceridemia

Publications (2)

Publication Number Publication Date
US20130004568A1 true US20130004568A1 (en) 2013-01-03
US8367652B2 US8367652B2 (en) 2013-02-05

Family

ID=42102041

Family Applications (29)

Application Number Title Priority Date Filing Date
US12/702,889 Active US8293727B2 (en) 2009-02-10 2010-02-09 Methods of treating hypertriglyceridemia
US13/198,221 Abandoned US20110288171A1 (en) 2009-02-10 2011-08-04 Methods of treating hypertriglyceridemia
US13/282,145 Active US8318715B2 (en) 2009-02-10 2011-10-26 Methods of treating hypertriglyceridemia
US13/284,408 Active US8314086B2 (en) 2009-02-10 2011-10-28 Methods of treating hypertriglyceridemia
US13/349,153 Active US8293728B2 (en) 2009-02-10 2012-01-12 Methods of treating hypertriglyceridemia
US13/349,150 Active US8324195B2 (en) 2009-02-10 2012-01-12 Methods of treating hypertriglyceridemia
US13/349,157 Active US8415335B2 (en) 2009-02-10 2012-01-12 Methods of treating hypertriglyceridemia
US13/403,694 Abandoned US20120156285A1 (en) 2009-02-10 2012-02-23 Methods of treating hypertriglyceridemia
US13/404,666 Abandoned US20120157530A1 (en) 2009-02-10 2012-02-24 Methods of treating hypertriglyceridemia
US13/482,720 Abandoned US20120237594A1 (en) 2009-02-10 2012-05-29 Methods of treating hypertriglyceridemia
US13/608,775 Active US8357677B1 (en) 2009-02-10 2012-09-10 Methods of treating hypertriglyceridemia
US13/608,744 Active US8426399B2 (en) 2009-02-10 2012-09-10 Methods of treating hypertriglyceridemia
US13/610,247 Active US8367652B2 (en) 2009-02-10 2012-09-11 Methods of treating hypertriglyceridemia
US13/610,217 Active US8399446B2 (en) 2009-02-10 2012-09-11 Methods of treating hypertriglyceridemia
US13/623,450 Active US8377920B2 (en) 2009-02-10 2012-09-20 Methods of treating hypertriglyceridemia
US13/711,324 Active US8440650B1 (en) 2009-02-10 2012-12-11 Methods of treating hypertriglyceridemia
US13/711,329 Active US8431560B1 (en) 2009-02-10 2012-12-11 Methods of treating hypertriglyceridemia
US13/776,242 Active US8518929B2 (en) 2009-02-10 2013-02-25 Methods of treating hypertriglyceridemia
US13/776,261 Active US8546372B2 (en) 2009-02-10 2013-02-25 Methods of treating hypertriglyceridemia
US13/776,249 Active US8524698B2 (en) 2009-02-10 2013-02-25 Methods of treating hypertriglyceridemia
US13/903,742 Abandoned US20130331447A1 (en) 2009-02-10 2013-05-28 Methods of treating hypertriglyceridemia
US15/408,077 Abandoned US20170119722A1 (en) 2009-02-10 2017-01-17 Methods of treating hypertriglyceridemia
US15/907,707 Abandoned US20180185320A1 (en) 2009-02-10 2018-02-28 Methods of treating hypertriglyceridemia
US16/029,198 Abandoned US20190038590A1 (en) 2009-02-10 2018-07-06 Methods of treating hypertriglyceridemia
US16/854,757 Abandoned US20200246300A1 (en) 2009-02-10 2020-04-21 Methods of treating hypertriglyceridemia
US17/009,597 Abandoned US20210046036A1 (en) 2009-02-10 2020-09-01 Methods of treating hypertriglyceridemia
US17/101,700 Abandoned US20210069142A1 (en) 2009-02-10 2020-11-23 Methods of treating hypertriglyceridemia
US17/153,494 Abandoned US20210251941A1 (en) 2009-02-10 2021-01-20 Methods of treating hypertriglyceridemia
US18/174,091 Pending US20240024277A1 (en) 2009-02-10 2023-02-24 Methods of treating hypertriglyceridemia

Family Applications Before (12)

Application Number Title Priority Date Filing Date
US12/702,889 Active US8293727B2 (en) 2009-02-10 2010-02-09 Methods of treating hypertriglyceridemia
US13/198,221 Abandoned US20110288171A1 (en) 2009-02-10 2011-08-04 Methods of treating hypertriglyceridemia
US13/282,145 Active US8318715B2 (en) 2009-02-10 2011-10-26 Methods of treating hypertriglyceridemia
US13/284,408 Active US8314086B2 (en) 2009-02-10 2011-10-28 Methods of treating hypertriglyceridemia
US13/349,153 Active US8293728B2 (en) 2009-02-10 2012-01-12 Methods of treating hypertriglyceridemia
US13/349,150 Active US8324195B2 (en) 2009-02-10 2012-01-12 Methods of treating hypertriglyceridemia
US13/349,157 Active US8415335B2 (en) 2009-02-10 2012-01-12 Methods of treating hypertriglyceridemia
US13/403,694 Abandoned US20120156285A1 (en) 2009-02-10 2012-02-23 Methods of treating hypertriglyceridemia
US13/404,666 Abandoned US20120157530A1 (en) 2009-02-10 2012-02-24 Methods of treating hypertriglyceridemia
US13/482,720 Abandoned US20120237594A1 (en) 2009-02-10 2012-05-29 Methods of treating hypertriglyceridemia
US13/608,775 Active US8357677B1 (en) 2009-02-10 2012-09-10 Methods of treating hypertriglyceridemia
US13/608,744 Active US8426399B2 (en) 2009-02-10 2012-09-10 Methods of treating hypertriglyceridemia

Family Applications After (16)

Application Number Title Priority Date Filing Date
US13/610,217 Active US8399446B2 (en) 2009-02-10 2012-09-11 Methods of treating hypertriglyceridemia
US13/623,450 Active US8377920B2 (en) 2009-02-10 2012-09-20 Methods of treating hypertriglyceridemia
US13/711,324 Active US8440650B1 (en) 2009-02-10 2012-12-11 Methods of treating hypertriglyceridemia
US13/711,329 Active US8431560B1 (en) 2009-02-10 2012-12-11 Methods of treating hypertriglyceridemia
US13/776,242 Active US8518929B2 (en) 2009-02-10 2013-02-25 Methods of treating hypertriglyceridemia
US13/776,261 Active US8546372B2 (en) 2009-02-10 2013-02-25 Methods of treating hypertriglyceridemia
US13/776,249 Active US8524698B2 (en) 2009-02-10 2013-02-25 Methods of treating hypertriglyceridemia
US13/903,742 Abandoned US20130331447A1 (en) 2009-02-10 2013-05-28 Methods of treating hypertriglyceridemia
US15/408,077 Abandoned US20170119722A1 (en) 2009-02-10 2017-01-17 Methods of treating hypertriglyceridemia
US15/907,707 Abandoned US20180185320A1 (en) 2009-02-10 2018-02-28 Methods of treating hypertriglyceridemia
US16/029,198 Abandoned US20190038590A1 (en) 2009-02-10 2018-07-06 Methods of treating hypertriglyceridemia
US16/854,757 Abandoned US20200246300A1 (en) 2009-02-10 2020-04-21 Methods of treating hypertriglyceridemia
US17/009,597 Abandoned US20210046036A1 (en) 2009-02-10 2020-09-01 Methods of treating hypertriglyceridemia
US17/101,700 Abandoned US20210069142A1 (en) 2009-02-10 2020-11-23 Methods of treating hypertriglyceridemia
US17/153,494 Abandoned US20210251941A1 (en) 2009-02-10 2021-01-20 Methods of treating hypertriglyceridemia
US18/174,091 Pending US20240024277A1 (en) 2009-02-10 2023-02-24 Methods of treating hypertriglyceridemia

Country Status (24)

Country Link
US (29) US8293727B2 (en)
EP (5) EP3037089B1 (en)
KR (2) KR101383006B1 (en)
AU (1) AU2010213899B2 (en)
BR (1) BRPI1007518A2 (en)
CA (3) CA3089847A1 (en)
CY (2) CY1122628T1 (en)
DK (3) DK2395991T3 (en)
ES (3) ES2426132T3 (en)
HK (2) HK1165698A1 (en)
HR (3) HRP20130811T1 (en)
HU (1) HUE048299T2 (en)
LT (2) LT2596786T (en)
MX (1) MX2011008448A (en)
NZ (1) NZ594395A (en)
PH (1) PH12015500407B1 (en)
PL (3) PL2395991T3 (en)
PT (3) PT2596786T (en)
RU (2) RU2505292C2 (en)
SG (3) SG10201400685SA (en)
SI (3) SI2596786T1 (en)
SM (1) SMT201300095B (en)
WO (1) WO2010093634A1 (en)
ZA (1) ZA201105612B (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140355057A1 (en) * 2013-06-03 2014-12-04 Samsung Electronics Co., Ltd Method and apparatus to write tag using near field communication
US9056088B2 (en) 2009-04-29 2015-06-16 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising fatty acids
US9060983B2 (en) 2009-04-29 2015-06-23 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
US9855240B2 (en) 2013-02-19 2018-01-02 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20180160284A1 (en) * 2015-04-30 2018-06-07 Lg Electronics Inc. Method and device for transmitting/receiving data using bluetooth mesh network
US10166209B2 (en) 2013-02-06 2019-01-01 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10314803B2 (en) 2008-09-02 2019-06-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10493058B2 (en) 2009-09-23 2019-12-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US10537544B2 (en) 2011-11-07 2020-01-21 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10668042B2 (en) 2018-09-24 2020-06-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US10842768B2 (en) 2009-06-15 2020-11-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides
US10888539B2 (en) 2013-09-04 2021-01-12 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US11141399B2 (en) 2012-12-31 2021-10-12 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US11179362B2 (en) 2012-11-06 2021-11-23 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11547710B2 (en) 2013-03-15 2023-01-10 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712428B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
CN102355896A (en) 2009-01-12 2012-02-15 拜奥基尔公司 Composition and method for treatment of diabetes
KR101383006B1 (en) 2009-02-10 2014-04-08 아마린 파마, 인크. Methods of treating hypertriglyceridemia
AU2010298303A1 (en) 2009-09-23 2012-04-12 Biokier, Inc. Composition and method for treatment of diabetes
WO2011087981A2 (en) 2010-01-15 2011-07-21 E. I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
RU2606853C2 (en) * 2010-03-04 2017-01-10 Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) Compositions and methods for treating and/or preventing cardiovascular disease
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
CN108524483A (en) 2012-01-06 2018-09-14 翁特拉制药公司 Ω -3 polyunsaturated fatty acids of free acid form are rich in DPA compositions
AU2013200820B2 (en) * 2012-02-14 2014-04-10 Fermentalg Method for supervising consumption of a medical food for prevention and/or management of a disease or condition
JP6173437B2 (en) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド Statins and omega-3 fatty acid compositions
KR20200074259A (en) 2012-05-15 2020-06-24 모치다 세이야쿠 가부시키가이샤 Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity c-reactive protein
AU2013277441B2 (en) 2012-06-17 2017-07-06 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
WO2014004993A2 (en) * 2012-06-29 2014-01-03 Amarin Pharmaceuticals Ireland Limited Methods of reducing ldl-p
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects
US20140005265A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating hypertriglyceridemia
EP2902020A4 (en) * 2012-09-28 2016-03-23 Mochida Pharm Co Ltd Composition for reducing new-onset diabetes
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US20140213648A1 (en) * 2012-12-31 2014-07-31 Amarin Pharmaceuticals Ireland Limited Methods of increasing epa blood levels
US20140221358A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US20140221452A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
JP2016518315A (en) * 2013-03-13 2016-06-23 マティナス バイオファーマ インコーポレイテッド ω3 pentaenoic acid composition and method of use
US20140357717A1 (en) * 2013-06-04 2014-12-04 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6804823B2 (en) * 2013-10-14 2020-12-23 アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティーArizona Board of Regents on behalf of Arizona State University Platinum complex and device
US10183044B2 (en) 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US11400082B2 (en) 2017-10-30 2022-08-02 Montréal Heart Institute Methods of treating elevated plasma cholesterol

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377526A (en) 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
US4526902A (en) 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
JPS6135356A (en) * 1984-07-27 1986-02-19 Nippon Oil & Fats Co Ltd Analyzing method of fatty acid in blood lipid
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5252333A (en) 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IE63225B1 (en) 1988-09-13 1995-04-05 Efamol Holdings Use of fatty acids in the treatment of myalgic encephalomyelitis
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (en) 1989-01-23 1998-12-16 日本分光工業株式会社 Supercritical fluid extraction / separation method and apparatus
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
US5457130A (en) 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
CA2043615C (en) 1990-06-04 2001-08-14 Kazuhiko Hata Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en) 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
JP3103588B2 (en) 1990-11-16 2000-10-30 持田製薬株式会社 Lipoprotein (a) lowering agent
SE9101642D0 (en) 1991-05-30 1991-05-30 Kabi Pharmacia Ab phospholipids
US5215630A (en) 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
WO1993003450A1 (en) * 1991-07-30 1993-02-18 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
DE4133694C2 (en) 1991-10-11 1993-10-07 Fresenius Ag Use of an emulsion with polyunsaturated fatty acids for i.v. administration for the treatment of skin diseases
JP3400466B2 (en) 1991-10-28 2003-04-28 日本水産株式会社 Method for producing high-purity eicosapentaenoic acid or ester thereof
JPH0649479A (en) 1992-07-28 1994-02-22 Maruha Corp Stabilization of omega,3-unsaturated fatty acid compound
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
WO1994028891A1 (en) 1993-06-04 1994-12-22 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
AU711482B2 (en) 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (en) 1994-08-25 1997-07-24 Prospa Bv PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACIDS, THEIR ESTERS OR SALTS, WITH VITAMINS OR ANTIOXIDANT PROVITAMINS
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9519661D0 (en) 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
AU2738497A (en) 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
TW425285B (en) 1996-06-10 2001-03-11 Viva America Marketing Inc Fish oil and garlic nutritive supplement
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
ES2195175T3 (en) 1996-10-11 2003-12-01 Scarista Ltd PHARMACEUTICAL PREPARATION THAT INCLUDES EICOSAPENTAENOIC ACID AND / OR ESTEARIDONIC ACID.
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
JP4309045B2 (en) 1997-10-30 2009-08-05 森下仁丹株式会社 Capsule preparation containing unsaturated fatty acid or derivative thereof and method for producing the same
CA2313024C (en) 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US20020055529A1 (en) 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
EP1072198B1 (en) 1999-07-28 2008-05-14 SWISS CAPS Rechte und Lizenzen AG Preparation for use as medicament and/or nutritional supplement
EP1211955A1 (en) 1999-08-30 2002-06-12 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
ES2246769T3 (en) 2000-05-22 2006-03-01 Pro Aparts - Investimentos E Consultoria Lda COMPOSITION OF FATTY ACIDS CONTAINING AT LEAST 80% IN WEIGHT OF EPA AND DHA OR ITS DERIVATIVES AND THEIR PHARMACEUTICAL USE.
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
EP1309329A2 (en) 2000-08-15 2003-05-14 Pfizer Products Inc. Therapeutic combination of a cetp inhibitor and atorvastatin
ITMI20010129A1 (en) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
US20020198177A1 (en) 2001-05-30 2002-12-26 Horrobin David Frederick Coenzyme Q and EPA
ITMI20012384A1 (en) 2001-11-12 2003-05-12 Quatex Nv USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS
ITMI20020269A1 (en) 2002-02-12 2003-08-12 Victorix Assets Ltd USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY
HUP0200686A2 (en) 2002-02-22 2003-09-29 EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. Electronic apparatus and method of taking part in games for guessing series of numbers by communication device
US20030166614A1 (en) 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
CA2390820A1 (en) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
AU2003257550A1 (en) 2002-08-20 2004-03-11 Nikken Chemicals Co., Ltd. Soft capsule preparation
EP1564278B1 (en) 2002-11-22 2018-01-10 Nippon Suisan Kaisha, Ltd. Composition containing organic substance having double bond with improved oxidation stability
GB0228079D0 (en) 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
JP2006519244A (en) 2003-03-05 2006-08-24 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of omega-3-fatty acids in the treatment of diabetic patients
NZ541516A (en) 2003-03-18 2008-05-30 Novartis Ag Compositions comprising fatty acids and amino acids
ITMI20032247A1 (en) 2003-11-19 2005-05-20 Tiberio Bruzzese INTERACTION OF POLAR DERIVATIVES OF COMPOUNDS INSATURATED WITH INORGANIC SUBSTRATES
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
WO2005114190A2 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Methods of identifying biomarkers
JP2007284350A (en) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd Therapeutic agent for diabetes
ITRM20040395A1 (en) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti COMPOSITION INCLUDING STATINES AND FATTY ACIDS OMEGA 3.
BRPI0514189A (en) 2004-08-06 2008-06-03 Transform Pharmaceuticals Inc statin pharmaceutical compositions and related treatment methods
WO2006030753A1 (en) 2004-09-13 2006-03-23 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctiva disorder
CN1759834B (en) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat
WO2006035417A2 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
EP1833313A2 (en) 2004-10-15 2007-09-19 Corporation Limited Photonz Compositions containing high omega-3 and low saturated fatty acid levels
FR2878747B1 (en) 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa USE OF OMEGA-3 FATTY ACID (S) FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA CAUSED BY ANTI-RETROVIRAL TREATMENT IN HIV INFECTED PATIENTS
US20070191467A1 (en) 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
EA014420B1 (en) 2004-12-06 2010-12-30 Релайэнт Фармасьютикалз, Инк. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20060135610A1 (en) 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US20060189682A1 (en) * 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
CN101208083A (en) 2005-03-08 2008-06-25 瑞莱恩特医药品有限公司 Treatment with statin and Omega-3 fatty acids and a combination product thereof
EP1790339B1 (en) 2005-07-08 2014-06-04 Mochida Pharmaceutical Co., Ltd. Composition for prevention of occurrence of cardiovascular event
RU2290185C1 (en) * 2005-07-26 2006-12-27 Дмитрий Николаевич Мясников Composition for normalization of lipid metabolism and reducing body mass and method for its preparing
CA2616806A1 (en) 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
ITMI20051560A1 (en) 2005-08-10 2007-02-11 Tiberio Bruzzese COMPOSITION OF N-3 FATTY ACIDS WITH HIGH CONCENTRATION OF EPA AND E-O DHA AND CONTAINING N-6 FATTY ACIDS
WO2007051065A2 (en) 2005-10-28 2007-05-03 Numerate, Inc. Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20070104779A1 (en) 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
CA2628305C (en) 2005-11-11 2014-05-06 Mochida Pharmaceutical Co., Ltd. Jelly composition
US7652068B2 (en) 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
EP1800675B1 (en) 2005-12-23 2011-05-18 N.V. Nutricia Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
CA2802892A1 (en) * 2006-02-07 2007-08-07 Mochida Pharmaceutical Co. Ltd. Composition for preventing recurrence of stroke
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
WO2007142118A1 (en) 2006-05-31 2007-12-13 Mochida Pharmaceutical Co., Ltd. Composition for preventing the occurrence of cardiovascular event in multiple risk patient
JP5658876B2 (en) 2006-07-05 2015-01-28 フォトンズ コーポレーション リミテッド Ultra high purity EPA and polar lipids produced in large-scale heterotrophic culture areas
US20090304784A1 (en) 2006-07-28 2009-12-10 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
EA018734B1 (en) 2006-10-10 2013-10-30 Релайэнт Фармасьютикалз, Инк. STATIN AND OMEGA-3 FATTY ACIDS FOR REDUCTION OF Apo-B LEVELS
US20080125490A1 (en) 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
JP5345402B2 (en) 2007-01-17 2013-11-20 持田製薬株式会社 Composition for preventing or treating diseases related to thrombus or embolism
US20100055175A1 (en) 2007-03-06 2010-03-04 James Nugent Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
CN101801416B (en) 2007-06-29 2012-10-24 武田药品工业株式会社 Sealmess capsule
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
CA2724983A1 (en) 2008-05-20 2009-11-26 Mochida Pharmaceutical Co., Ltd. Composition for preventing cardiovascular event in high-risk patient
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
KR101383006B1 (en) 2009-02-10 2014-04-08 아마린 파마, 인크. Methods of treating hypertriglyceridemia
CN102458109B (en) 2009-04-29 2015-02-11 阿马里纳制药公司 Stable pharmaceutical composition and methods of using same
NZ620473A (en) 2009-06-15 2015-09-25 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides without raising ldl-c levels
SG190025A1 (en) 2010-11-04 2013-06-28 Hoffmann La Roche A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10314803B2 (en) 2008-09-02 2019-06-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US11103477B2 (en) 2009-04-29 2021-08-31 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US11154526B2 (en) 2009-04-29 2021-10-26 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US11033523B2 (en) 2009-04-29 2021-06-15 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
US10265287B2 (en) 2009-04-29 2019-04-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing triglycerides and LDL-C
US9585856B2 (en) 2009-04-29 2017-03-07 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US10220013B2 (en) 2009-04-29 2019-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US11690820B2 (en) 2009-04-29 2023-07-04 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US10624870B2 (en) 2009-04-29 2020-04-21 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US9060983B2 (en) 2009-04-29 2015-06-23 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US11400069B2 (en) 2009-04-29 2022-08-02 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US11213504B2 (en) 2009-04-29 2022-01-04 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US10842766B2 (en) 2009-04-29 2020-11-24 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US11147787B2 (en) 2009-04-29 2021-10-19 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9056088B2 (en) 2009-04-29 2015-06-16 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising fatty acids
US10449172B2 (en) 2009-04-29 2019-10-22 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9060982B2 (en) 2009-04-29 2015-06-23 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9855237B2 (en) 2009-04-29 2018-01-02 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US10987331B2 (en) 2009-04-29 2021-04-27 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US10940131B2 (en) 2009-04-29 2021-03-09 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US10888537B2 (en) 2009-04-29 2021-01-12 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising omega-3 fatty acids
US10010517B2 (en) 2009-04-29 2018-07-03 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US10881632B2 (en) 2009-04-29 2021-01-05 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US10792267B2 (en) 2009-04-29 2020-10-06 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US11439618B2 (en) 2009-06-15 2022-09-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides
US10842768B2 (en) 2009-06-15 2020-11-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides
US11464757B2 (en) 2009-06-15 2022-10-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides
US10493058B2 (en) 2009-09-23 2019-12-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11007173B2 (en) 2009-09-23 2021-05-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712428B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US10632094B2 (en) 2011-11-07 2020-04-28 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10537544B2 (en) 2011-11-07 2020-01-21 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
US10973796B2 (en) 2012-01-06 2021-04-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (hs-CRP) in a subject
US9693984B2 (en) 2012-06-29 2017-07-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10792270B2 (en) 2012-06-29 2020-10-06 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10278938B2 (en) 2012-06-29 2019-05-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10278937B2 (en) 2012-06-29 2019-05-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10278939B2 (en) 2012-06-29 2019-05-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10555925B1 (en) 2012-06-29 2020-02-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10555924B2 (en) 2012-06-29 2020-02-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US9918955B2 (en) 2012-06-29 2018-03-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10568861B1 (en) 2012-06-29 2020-02-25 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10576054B1 (en) 2012-06-29 2020-03-03 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10383840B2 (en) 2012-06-29 2019-08-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US9693985B2 (en) 2012-06-29 2017-07-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9610272B2 (en) 2012-06-29 2017-04-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9623001B2 (en) 2012-06-29 2017-04-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10278936B2 (en) 2012-06-29 2019-05-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9918954B2 (en) 2012-06-29 2018-03-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10278935B2 (en) 2012-06-29 2019-05-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10894028B2 (en) 2012-06-29 2021-01-19 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10016386B2 (en) 2012-06-29 2018-07-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9693986B2 (en) 2012-06-29 2017-07-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US11179362B2 (en) 2012-11-06 2021-11-23 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11229618B2 (en) 2012-11-06 2022-01-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11141399B2 (en) 2012-12-31 2021-10-12 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US10675263B2 (en) 2013-02-06 2020-06-09 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US11185525B2 (en) 2013-02-06 2021-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US10166209B2 (en) 2013-02-06 2019-01-01 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US10610508B2 (en) 2013-02-06 2020-04-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US10265290B2 (en) 2013-02-06 2019-04-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US10973797B2 (en) 2013-02-06 2021-04-13 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein c-III
US10851374B2 (en) 2013-02-13 2020-12-01 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US10167467B2 (en) 2013-02-13 2019-01-01 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9855240B2 (en) 2013-02-19 2018-01-02 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US10206898B2 (en) 2013-03-14 2019-02-19 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US11547710B2 (en) 2013-03-15 2023-01-10 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US20140355057A1 (en) * 2013-06-03 2014-12-04 Samsung Electronics Co., Ltd Method and apparatus to write tag using near field communication
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US10888539B2 (en) 2013-09-04 2021-01-12 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10292959B2 (en) 2013-10-10 2019-05-21 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11285127B2 (en) 2013-10-10 2022-03-29 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10722485B2 (en) 2013-10-10 2020-07-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US11052063B2 (en) 2014-06-11 2021-07-06 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US11446269B2 (en) 2014-06-16 2022-09-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US20180160284A1 (en) * 2015-04-30 2018-06-07 Lg Electronics Inc. Method and device for transmitting/receiving data using bluetooth mesh network
US10842765B2 (en) 2016-03-15 2020-11-24 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US11369582B2 (en) 2018-09-24 2022-06-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US10668042B2 (en) 2018-09-24 2020-06-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US11298333B1 (en) 2018-09-24 2022-04-12 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US10786478B2 (en) 2018-09-24 2020-09-29 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US11000499B2 (en) 2018-09-24 2021-05-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US11116743B2 (en) 2018-09-24 2021-09-14 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US11116742B2 (en) 2018-09-24 2021-09-14 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US11717504B2 (en) 2018-09-24 2023-08-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject

Also Published As

Publication number Publication date
ZA201105612B (en) 2012-10-31
US20130017256A1 (en) 2013-01-17
HK1226307A1 (en) 2017-09-29
US8426399B2 (en) 2013-04-23
RU2011137415A (en) 2013-03-20
US8293728B2 (en) 2012-10-23
PL2395991T3 (en) 2013-11-29
US20100311834A1 (en) 2010-12-09
ES2768091T3 (en) 2020-06-19
DK2395991T3 (en) 2013-09-02
AU2010213899A1 (en) 2011-08-25
US8318715B2 (en) 2012-11-27
RU2686315C2 (en) 2019-04-25
CA2751576A1 (en) 2010-08-19
MX2011008448A (en) 2012-02-28
DK2596786T3 (en) 2020-02-24
PL3037089T3 (en) 2020-06-01
RU2019111131A (en) 2020-10-15
SI2596786T1 (en) 2020-03-31
PT2395991E (en) 2013-09-03
US20120108659A1 (en) 2012-05-03
PT2596786T (en) 2020-03-04
US20200246300A1 (en) 2020-08-06
KR101383006B1 (en) 2014-04-08
US8415335B2 (en) 2013-04-09
PH12015500407A1 (en) 2015-09-21
DK3037089T3 (en) 2020-01-20
KR20110110321A (en) 2011-10-06
US20130171249A1 (en) 2013-07-04
US8440650B1 (en) 2013-05-14
US20120093924A1 (en) 2012-04-19
CA2751576C (en) 2018-07-03
HUE048299T2 (en) 2020-07-28
RU2013154780A (en) 2015-06-20
US20190038590A1 (en) 2019-02-07
EP2395991A1 (en) 2011-12-21
PL2596786T3 (en) 2020-06-01
EP2596786B1 (en) 2019-11-27
AU2010213899B2 (en) 2014-02-06
US8518929B2 (en) 2013-08-27
HRP20200065T1 (en) 2020-04-03
RU2505292C2 (en) 2014-01-27
US20170119722A1 (en) 2017-05-04
US8357677B1 (en) 2013-01-22
US20120157530A1 (en) 2012-06-21
EP2395991B1 (en) 2013-05-29
HK1165698A1 (en) 2012-10-12
US20130331447A1 (en) 2013-12-12
SG173612A1 (en) 2011-09-29
EP3865128A1 (en) 2021-08-18
US8546372B2 (en) 2013-10-01
CA3008079A1 (en) 2010-08-19
US20240024277A1 (en) 2024-01-25
US20210046036A1 (en) 2021-02-18
US20130164375A1 (en) 2013-06-27
EP3037089A1 (en) 2016-06-29
US8399446B2 (en) 2013-03-19
US8431560B1 (en) 2013-04-30
US20120108663A1 (en) 2012-05-03
ES2769926T3 (en) 2020-06-29
US20180185320A1 (en) 2018-07-05
US20130005809A1 (en) 2013-01-03
US20130004566A1 (en) 2013-01-03
PT3037089T (en) 2020-03-04
SG10201610916SA (en) 2017-02-27
EP2596786A1 (en) 2013-05-29
US20120237594A1 (en) 2012-09-20
EP3037089B1 (en) 2019-11-27
WO2010093634A1 (en) 2010-08-19
SI3037089T1 (en) 2020-03-31
LT2596786T (en) 2020-01-10
US20120039997A1 (en) 2012-02-16
HRP20200068T1 (en) 2020-04-03
US20130096197A1 (en) 2013-04-18
SI2395991T1 (en) 2013-12-31
LT3037089T (en) 2020-01-10
US20130171250A1 (en) 2013-07-04
US20120156285A1 (en) 2012-06-21
US20130102674A1 (en) 2013-04-25
US20210069142A1 (en) 2021-03-11
NZ594395A (en) 2014-01-31
US8314086B2 (en) 2012-11-20
PH12015500407B1 (en) 2015-09-21
US8367652B2 (en) 2013-02-05
US8524698B2 (en) 2013-09-03
SG10201400685SA (en) 2015-01-29
US20110288171A1 (en) 2011-11-24
SMT201300095B (en) 2013-11-08
HRP20130811T1 (en) 2013-09-30
US20120108660A1 (en) 2012-05-03
CY1122629T1 (en) 2021-03-12
US20210251941A1 (en) 2021-08-19
US20130004567A1 (en) 2013-01-03
CA3089847A1 (en) 2010-08-19
ES2426132T3 (en) 2013-10-21
CY1122628T1 (en) 2021-03-12
KR20140007973A (en) 2014-01-20
EP3616694A1 (en) 2020-03-04
US8324195B2 (en) 2012-12-04
BRPI1007518A2 (en) 2018-02-20
CA3008079C (en) 2020-09-22
US8377920B2 (en) 2013-02-19
US8293727B2 (en) 2012-10-23

Similar Documents

Publication Publication Date Title
US20240024277A1 (en) Methods of treating hypertriglyceridemia

Legal Events

Date Code Title Description
AS Assignment

Owner name: AMARIN PHARMA, INC., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MANKU, MEHAR;OSTERLOH, IAN;WICKER, PIERRE;AND OTHERS;SIGNING DATES FROM 20100808 TO 20100822;REEL/FRAME:029139/0121

Owner name: AMARIN PHARMACEUTICALS IRELAND LIMITED, IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AMARIN PHARMA INC.;REEL/FRAME:029139/0139

Effective date: 20120313

AS Assignment

Owner name: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP,

Free format text: SECURITY AGREEMENT;ASSIGNOR:AMARIN PHARMACEUTICALS IRELAND LIMITED;REEL/FRAME:029499/0087

Effective date: 20121219

Owner name: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP, CAYMAN ISLANDS

Free format text: SECURITY AGREEMENT;ASSIGNOR:AMARIN PHARMACEUTICALS IRELAND LIMITED;REEL/FRAME:029499/0087

Effective date: 20121219

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: CPPIB CREDIT EUROPE S.A R.L., LUXEMBOURG

Free format text: PATENT SECURITY ASSIGNMENT AND ASSUMPTION AGREEMENT;ASSIGNOR:BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP;REEL/FRAME:044956/0395

Effective date: 20171220

AS Assignment

Owner name: CPPIB CREDIT EUROPE S.A R.L., LUXEMBOURG

Free format text: SECURITY INTEREST;ASSIGNOR:AMARIN PHARMACEUTICALS IRELAND LIMITED;REEL/FRAME:044938/0257

Effective date: 20171220

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

AS Assignment

Owner name: AMARIN PHARMACEUTICALS IRELAND LIMITED, IRELAND

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CPPIB CREDIT EUROPE S.A R.L.;REEL/FRAME:054484/0552

Effective date: 20201119